Protocol Number PTG-300-[ADDRESS_808782] Therapeutics, Inc. 
Protocol Amendment 3 â€“ 14 September  2020 
CONFIDENTIAL AND PROPRIETARY  1 of 67 Op
en-label Study of PTG -300 in Subjects  with Hereditary Hemochromatosis  
Protocol Number: PTG-300-06
 [STUDY_ID_REMOVED] 
Development Phase: Phase 2 
Document Version: Protocol Amendment 3, dated [ADDRESS_808783] Therapeutics, Inc. 

,*.**' /( , 
 ,*."*)$-. # ,+ /.$- )
,*.**' ( )( ).  3 	  +. ( , 

    *! 
	



 
		

 

 + )' ' ./2 *!   $) /% .- 1$.#  , $.,2  (*# ,*(.*-$-
#$- -./2 +,*.**' 1- -/% .  .* ,$.$' , 0$ 1 # $)!*, (.$*) $. *).$)- $- *)-$-. ).
1$.# /,, ). &)*1' " *! .# , $-&- )  ) !$.- *! .# $)0 -.$ ".$*)' +,*/.  - 1 '' - 1$.#
.# (*,'  .#$' ) -$ ).$!$ +,$)$+' - "*0 ,)$)" '$)$ ' , - ,# - - . */. $) .# /,, ).
 ',.$*) *!  '-$)&$ ) . # "/$ '$) - *) ** 
'$)$' , .$ 

#$ !  0 '*+( ). !!$ , 
'$)$'  0 '*+( ).
,*."*)$-. # ,+ /.$-
$")
./, . September 17, [ADDRESS_808784] Therapeutics, Inc. 
Protocol Amendment 3 â€“ 14 September  2020 
CONFIDENTIAL AND PROPRIETARY  3 of 67 INVESTIGATORâ€™S AGREEMENT  
 
Protocol No.:   PTG -300-06 
Protocol Title:   Open -label  Study of PTG-[ADDRESS_808785] confidence. This documentation includes this study protocol, Investigator's Brochure(s) (IB), Case Report Form s (CRFs), and other scientific data.  
The study will not be commenced without the prior written approval of a properly constituted Institutional Review Board (IRB). No changes will be made to the study protocol without the prior written approval of the Sponsor and the IRB, except where necessary to avert an immediate hazard to the subjects.  
I have read the protocol and agree that the study will be conducted in compliance with the protocol and in accordance with the principles of the current version of the De claration of 
Helsinki (Ethical Principles for Medical Research Involving Human Subjects), and with [ADDRESS_808786] of the study will be in accordance with the Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice ICH E6(R2) and applicable parts of [ADDRESS_808787] to ensure that site staff receive the appropriate information throughout 
the study. 
 
   
Investigator Name (Print)   Investigational Site  
   
 
     
Investigator Signature  [CONTACT_610012]-300-[ADDRESS_808788] Therapeutics, Inc. 
Protocol Amendment 3 â€“ 14 September  2020 
CONFIDENTIAL AND PROPRIETARY  4 of 67 2. SYNOPSIS  
 
Name [CONTACT_790]/Company:  Protagonist Therapeutics, Inc.  
Name [CONTACT_791]:  PTG -300 
Protocol Number:  PTG -300-06 Country:  Multiple  
Title of Study: Open -label Study of PTG-300 in Subjects with Hereditary Hemochromatosis 
Study center(s): Multicenter  
Phase of development: 2  
Indication:  Hereditary hemochromatosis (HH)  
Objectives:  
1. To assess the safety and tolerability of PTG -[ADDRESS_808789] of PTG -300 therapy on transferrin saturation (TSAT) and serum ferritin . 
3. To assess the effect of PTG -300 on iron absorption in a subset of subjects . (For subjects 
participating in the iron absorption substudy). 
4. To assess PTG -300â€™s efficacy for treating HH subjects as defined by [CONTACT_609991]. 
5. To assess the effect of PTG -300 on quality of life (QoL). 
6. To assess the pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of 
PTG -300. 
Study Design:  
This is a multicenter, single -arm, open- label study in subjects with HH. Subjects will receive 
subcutaneous PTG-300 for up to 24 weeks. Subjects will start at an initial dose of 10 mg per week 
subcutaneously. The dose may be increased to 20 mg per week, and subsequently to 40 mg and to 
80 mg per week if needed, based on tolerability and the pharmacodynamic marker TSAT . In addition, 
subcutaneous dosing schedules of 10 mg , 20 mg, and 40 mg twice weekly (Day 1 and either Day 4 or 
Day 5) may be tested.  
Subjectsâ€™ safety and blood iron parameters ( serum iron, serum ferritin, transferrin, and TSAT ) will be 
collected  to monitor  the pharmacodynamic effect of PTG -300. Effect on phlebotomy need and QoL 
data ( 36-Item Short Form Health Survey [ SF-36], and  Patientâ€™s Global Impression of Change 
[PGI-C]) will also be collected and tabulated. 
A subset of subjects (approximately 6 subjects) will participate in a two -way crossover sequential iron 
(57Fe) absorption substudy. The oral iron absorption substudy  will be conducted once during the 
3-week screening period  and then following approximately 4 to 6 weeks of PTG -300 treatment. 
Methodology: 
Screening (Study Day -21 to - 1) 
After giving written informed consent, subjects will be screened for eligibility according to 
inclusion/exclusion criteria (see Diagnosis and Main Criteria for Inclusion  section) within 2 1 days of 
dosing. Subjects will continue their individual iron restri cted diet throughout the study. During this 
period l iver iron concentration (LIC) will be assessed by [CONTACT_9252] (MRI) . 
Subjects will begin treatment with PTG -[ADDRESS_808790] Therapeutics, Inc. 
Protocol Amendment 3 â€“ 14 September  2020 
CONFIDENTIAL AND PROPRIETARY  5 of 67 phlebotomy, with iron paramet ers measured before (Screening labs) and after the phlebotomy  (pre-
dose Study Day 1) . Each individual subjectâ€™s pre-phlebotomy serum  ferritin level and TSAT will be 
used as a criterion for phlebotomy  during the study, i.e., the threshold at which a phlebotomy should 
be considered during the study. The serum ferritin level and TSAT obtained during Screening will be 
used as baseline to assess the change from these measurements post -dosing with PTG -300. 
After eligibility has been c onfirmed, subjects will be enrolled in the study. 
Treatment Period (Week 1 to Week 25)  
Study Drug Administration: Dosing with PTG-[ADDRESS_808791] subcutaneous (SC) injection at the clinic and will be instructed on how to self- administer the 
injection (or have a caregiver administer the injection) and on appropriate safety monitoring before being discharged.  
On Study Day 2, subjects will return to the clinic for serum iron parameters and PTG -300 blood 
concentration  (PK) measurements.  
Individual Subject Dose and Schedule Escalation : Individual subject dose and schedule will be 
determined  based on the pharmacodynamic (PD) marker TSAT measured at two time points: once at 
peak PD  effect one day post dose and once at trough PD effect. The intent of dose and schedule 
adjustment is to  reduc e TSAT and serum iron levels. The dose of PTG-300 may be increased weekly 
in a sequential manner from 10 mg to 20 mg and, if necessary, to 40 mg and 80 mg until the TSAT is 
less than approximately 40 % at peak PD  effect one day post dose and at the trough PD effect prior to 
the next dose of PTG -300. In addition, the dose may be adjusted to maintain serum ferritin to no more 
than 1.5 times the screening value or 150 ng/mL, whichever is greater. Investigators may consider 
once a week or twice a week dosing of PTG -[ADDRESS_808792] is 
the TSAT value  measured 7 days after the PTG -300 dose (and before the next dose) for once weekly 
dosing or [ADDRESS_808793] 3 days apart (e.g., on Day 1 and Day 4 or 5 of each week). The twice weekly  PTG -300 dose may be escalated to a maximum of 40 mg twice weekly . To fa cilitate 
dose escalation and the identification  of a therapeutic dose, investigators may assess TSAT values on 
days subjects come to the clinic for any dose adjustments . These assessments may occur at times 
other than the regular sched uled visits  indicated on the schedule of events . 
Subjects will continue treatment by [CONTACT_6270]- administering PTG -300 at home (or in the c linical center as 
appropriate) for up to 24 weeks based on acceptable safety and tolerability of the drug (see Safety 
Monitoring). Subjects will return for clinic visits to have safety  assessments; serum iron parameters 
plus soluble transferrin receptor  (sTfR ), hepcidin and antidrug antibodies ( ADA) ; and efficacy 
evaluated according to the schedule of assessments.  
Subjectsâ€™ iron parameters will be monitored throughout the study.  
Change in Starting Dose : The starting dose may be increased from 10 mg to 20 mg, 40 mg, or 80 mg 
as appropriate if <[ADDRESS_808794] 4 subjects (or â‰¤25% of a larger number of subjects) treated at a given 
dose have both peak and trough TSAT values approximately <40% and no safety signals have been noted. 
Criteria for a Phlebotomy: Subjects should undergo an on-study phlebotomy when the subjectâ€™s 
serum f erritin levels and  TSAT value are higher than the pre- phlebotomy serum ferritin and TSAT 
values obtained during Screening. In addition, a phlebotomy may be performed when the Investigator assesses it is necessary for subject care.  
Protocol Number PTG-300-[ADDRESS_808795] Therapeutics, Inc. 
Protocol Amendment 3 â€“ [ADDRESS_808796] of the study 
population. 
Subjects consenting to participate in the iron absorption  substudy will receive the stable iron isotope 
57Fe orally (approximately 4 mg as ferrous sulfate) on two occasions ; once prior to starting PTG-300 
(i.e., a fter the phlebotomy performed during the Screening period; Iron Absorption A),  and a second 
dose approximately 4 to 6 weeks after starting PTG -300 (i.e., post -treatment; Iron Absorption B) . The 
post- treatment Iron Absorption B administration will occur approximately [ADDRESS_808797] for 
approximately 4 hours after the 57Fe dose. Blood samples will be collected at 0, 4, 8, 12, and 24 hours 
for measurement of 57Fe levels  and for measurement of  iron parameters â€”serum iron, serum ferritin, 
transferrin, and TSAT . Add itional blood sam ples will be obtained at 0, 4, 8, 12, and [ADDRESS_808798]-Treatment / Early Termination Safety Follow -up (Week 29)  
Subjects who complete the treatment or who discontinue treatment early will undergo Visit 8 /end of 
treatment (EOT) assessments as well as follow -up safety evaluations approximately [ADDRESS_808799] dose of study drug (Visit 9/end of study [EOS]). 
Safety Monitoring: Safety will be monitored throughout the study.  
Safety measures ( including but not limited to physical examinations, clinical laboratory tests , 
complete blood count [ CBC ], vital signs, electrocardiograms [ ECGs ], adverse event monitoring 
[AEs], and concomitant medications) will be evaluated and recorded over the course of the study. 
Any adverse event (AE) that emerges from the time the subject signs an informed consent form (ICF) 
until Study Exit will be recorded and reported. Safety will be assessed using the National Institutes of 
Health (NIH) Common Terminology Criteria for Adverse Events (CTCAE) v5.[ADDRESS_808800] one of the following criteria will require  a dose reduction: 
â€¢ CTCAE Grade 3 hematological toxicity or worsening of â‰¥2 grades in hematological parameters not clearly resulting from the underlying disease and/or without a clear-cut 
alternative that does not respond adequately to medical therapy. 
â€¢ CTCAE Grade 3 non- hematological toxicities not clearly resulting from the underlying 
disease and/or without a clear -cut alternative that does not respond adequately to medical 
therapy. 
â€¢ Treatment -related decrease of hemoglobin ( Hgb) from baseline >20% or Grade 2 anemia, 
whichever is lesser, confirmed by a repeat value and not due to phlebotomy. Prior to 
resumption of PTG -300 at a reduced dose a follow -up Hgb should be assessed to confirm that 
Hgb has stabilized or improved to Grade 1. 
â€¢ Investigator determines that the subject has experienced a clinically significan t decrease in 
Hgb due to PTG-300. 
If a treatment -related  increase in aspartate aminotransferase (AST) or alanine aminotransferase (ALT) 
>3 Ã— upper limit of normal (ULN) is seen, dosing with PTG-[ADDRESS_808801] and/or ALT levels return to baseline within 14 days; if the levels do not 
return to baseline within 14 days, a magnetic resonance imaging ( MRI ) should be conducted to assess 
whether there is an increase in iron accumulation . 
Protocol Number PTG-300-[ADDRESS_808802] Therapeutics, Inc. 
Protocol Amendment 3 â€“ [ADDRESS_808803] from further treatment with study drug:  
â€¢ Any CTCAE Grade 4 hematological or non -hematological toxicity  not clearly resulting from 
the underlying disease and/or without a clear- cut alternative . 
â€¢ CTCAE Grade 3 hematological toxicity or worsening of â‰¥2 grades in hematological 
parameters not clearly resulting from the underlying diseas e and/or without a clear-cut 
alternative persists over 7 days after adequate PTG -300 dose decrease.  
â€¢ CTCAE Grade 3 non- hematological toxicities not clearly resulting from the underlying 
disease and/or without a clear -cut alternative explanation that do not improve within 14 days 
with maximal medical therapy and adequate PTG -300 dose decrease.  
â€¢ When the Investigator in consultation with the medical monitor ( MM) consider s that it is in 
the subjectâ€™s best interest to discontinue treatment with PTG -300 (i.e., persistent, worsening 
or recurrent AEs).  
â€¢ If a subject requires a dose reduction below 10 mg administered every 2 weeks. 
â€¢ ALT, AST >5 Ã— ULN and rising . 
â€¢ ALT, AST remains >5 Ã— ULN w ith no change in total bilirubin for more than 2 weeks . 
â€¢ A worsening of clinical symptoms with no other acceptable explanation. 
â€¢ The product meets Hyâ€™s Law 
â€” Any test showing an increase of serum ALT >3 Ã— ULN or >2 Ã— ULN total bilirubin 
should be repeated within [ADDRESS_808804], alkaline phosphatase (ALP), 
and total bilirubin . If the repeat value for ALT or total bilirubin is unchanged or indicates 
decreasing activity, monitoring should continue at weekly intervals until the results are 
acceptable o r normalized. 
â€¢ Evidence of increased iron accumulation in liver from baseline.  
Number of subjects (planned): Approximately [ADDRESS_808805] 16 weeks of treatment. Approximately 6 subjects will participate 
in the iron absorption substudy. 
Diagnosis and main criteria for inclusion:  
Inclusi on Criteria : Subjects must meet ALL of the following inclusion criteria to be enrol led: 
1. Male and female subjects aged [ADDRESS_808806] a confirmed diagnosis of HFE- related hereditary hemochromatosis with prior genotype 
testing.  
3. Documented stable phl ebotomy for â‰¥ 6 months prior to screening; with a phlebotomy 
frequency of at least 0.25 per month ( e.g., received at least three phlebotomies over the 
previous [ADDRESS_808807] four phlebotomies over the previous 15 months) and a 
phlebotomy frequency of less than 1 per month . 
4. Screening hemoglobin >11.5 g/dL. 
5. Serum ferritin <300 ng/mL at screening  (before screening phlebotomy) . 
Protocol Number PTG-300-[ADDRESS_808808] Therapeutics, Inc. 
Protocol Amendment 3 â€“ 14 September  2020 
CONFIDENTIAL AND PROPRIETARY  8 of 67 6. Women of childbearing potential (WOCBP) and men with partners of childbearing potential 
agree to use a highly effective contraceptive measure (based on the Clinical Trials Facilitation 
Group [ CTFG ]) during the duration of the study and for [ADDRESS_808809] understands the study procedures, is willing and able to adhere to study requirements 
and agrees to participate in the study by [CONTACT_109348]. 
Exclusion Criteria : Subjects must meet NONE of the following exclusion criteria to be enrolled: 
1. Clinically meaningful laboratory abnormalities at Screening including, but not limited to:  
a. Absolute neutrophil count <1000/ÂµL  
b. Platelet count <100,000/ÂµL 
c. Estimated Glomerular Filtration Rate (eGFR) <40 mL/min/1.73 m2 
d. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) â‰¥2.5 Ã— upper limit 
of normal (ULN) or direct bilirubin >1.5 Ã— ULN  
e. C-reactive protein (CRP) â‰¥5.0 mg/L.  
2. Receiving iron chelation therapy. 
3. Receiving erythrocytapheresis.  
4. Pregnant or lactating females. 
5. Infection requiring hospi[INVESTIGATOR_609983], or opportunistic 
infection within 3 months of dosing; any infection requiring antimicrobial therapy within 
4 weeks of dosing. Prop hylactic antibiotics are allowed . 
6. Any serious or unstable medical or psychiatric condition that would prevent (as judged by [CONTACT_3786]) the subject from properly providing informed consent or any condition which 
would jeopardize compliance with the study or assessment of the studyâ€™s endpoints. 
7. Organ damage from iron overload, that (as judged by [CONTACT_737]) may be worsened by 
[CONTACT_609992]. 
8. Known primary or secondary immunodeficiency. 
9. Known history of autoimmune/inflammatory diseases. 
10. Positive for active hepatitis B or hepatitis C or known human immunodeficiency virus (HIV) 
infection. Active hepatitis B is defined as a known positive hepatitis B  surface antigen  
(HBsAg) result. Active hepatitis C is defi ned by a positive hep C Ab result and known 
quantitative hepatitis C virus (HCV) ribonucleic acid  (RNA) results greater than the lower 
level of detection of the assay. Subjects who have a history of HCV infection but have documented sustained virologic response 12 weeks after HCV therapy (SVR12) are eligible. 
11. Any surgical procedure requiring general anesthesia within 1 month prior to screening or planned elective surgery during the study (within 3 months for joint replacement surgery).  
12. History of invasive malignancies within the last 2 years, except non- melanoma skin cancer 
and localized cured prostate cancer, cervical cancer, and ductal carcinoma in situ (DCIS) . 
13. Current or recent history of alcohol dependence or illicit drug use within [ADDRESS_808810] Therapeutics, Inc. 
Protocol Amendment 3 â€“ [ADDRESS_808811](s), dose, and mode of administration : This study is a single -arm, open- label study.  
PTG -300 is formulated in an aqueous buffered solution and pre-filled at 0.5 mL and 1.0 mL into a 
1-mL glass syringe. Study drug will be administered by [CONTACT_6567] (SC) injections either weekly  or 
twice weekly , using a needle and a pre- filled syringe.  
Subjects will receive doses of 10 mg to 80 mg SC  weekly or 10 mg to 40 mg SC twice weekly. 
57Fe (~4 mg) is provided by [CONTACT_609993] a ferrous sulfate solution for oral administration . 
Duration of treatment: Individual subjects will participate in this study for up to 31 weeks as 
follows: 
â€¢ Screening: Up to 3 weeks 
â€¢ PTG -300 Treatment: Up to 24 weeks 
â€¢ Safety F ollow -Up: 4 weeks 
Study endpoints:  
Baseline D efinition: The serum ferritin level and TSAT obtained during S creening will be used as 
baseline.  
Efficacy:  
â€¢ Change from baseline in serum ferritin.  
â€¢ Duration of time that serum ferritin is below baseline measurement. 
â€¢ Change from baseline  in TSAT.  
â€¢ Duration of time that TSAT is below baseline measurement . 
â€¢ Time to first phlebotomy  after dosing. 
â€¢ Change in frequency of phlebotomies based on historical phlebotomy data  (24 weeks). 
â€¢ Proportion of subjects who achieve phlebotomy independence. 
â€¢ Additional Endpoints: 
âˆ’ SF-36 
âˆ’ PGI-C 
âˆ’ Change in iron absorption following administration of PTG -300. (For subjects 
completing iron absorption substudy.) 
âˆ’ PTG -300 pharmacokinetics: PTG-[ADDRESS_808812] dose.  
âˆ’ PD: Change from baseline in serum iron, transferrin, and sTfR.  
âˆ’ Change from baseline in LIC assessed by [CONTACT_9268] . 
âˆ’ Incidence of ADA.  
Protocol Number PTG-300-[ADDRESS_808813] Therapeutics, Inc. 
Protocol Amendment 3 â€“ 14 September  2020 
CONFIDENTIAL AND PROPRIETARY  10 of 67 Safety: 
â€¢ Tabulate frequency of treatment- emergent adverse events (TEAEs) and SAEs; treatment -
related TEAEs and SAEs; TEAEs leading to study discontinuation. 
â€¢ Summarize vital signs, safety laboratory assessments, ECGs, and physical examination 
findings. 
Statistical methods: This trial is exploratory and no rigid criteria for sample size are pre-specified. 
The choices are based on risk/benefit assessment of accumulating results. However, there will be at 
least 80% power for a sample size of [ADDRESS_808814] a 50% reductio n in the number of 
phlebotomies from baseline. The power calculation is based on a hypothesized effect size of 0.5 (mean change = 1, with SD = 2) over [ADDRESS_808815] at alpha = 10% 
level.  Twenty -eight (28) subjects will be  enrol led in the study, assuming an approximate 25% 
dropout. 
Summary statistics for all efficacy and PK/PD data will be provided. Frequency distribution for 
adverse events and summary statistics for laboratory assessments, ECGs and vital signs will be provided. 
Protocol Number PTG-300-[ADDRESS_808816] Therapeutics, Inc. 
Protocol Amendment 3 â€“ [ADDRESS_808817] OF 
FIGURES 
TABLE OF CONTENTS  
1. TITLE PAGE  ................................................................................................................1  
SIGNATURE [CONTACT_1783]  .......................................................................................................................2  
INVESTIGATORâ€™S AGREEMENT  ...............................................................................................[ADDRESS_808818] OF ABBREVIATIONS AND DEFINITIONS OF TERMS .............................15  
5. INTRODUCTION  ......................................................................................................18  
5.1. Background .................................................................................................................18  
5.1.1.  Rationale for the Development of PTG-300 ...............................................................18  
5.2. Summary of Nonclinical and Clinical Studies ............................................................19  
5.2.1.  Nonclinical Studies  .....................................................................................................19  
5.2.2.  Clinical Studies  ...........................................................................................................20  
5.3. Study Design and Target Population ..........................................................................21  
5.4. Selection of Doses  ......................................................................................................21  
5.5. Summary of Potential Risks and Benefits ..................................................................21  
6. OBJECTIVES  .............................................................................................................23  
7. INVESTIGATIONAL PLAN  .....................................................................................24  
7.1. Overall Study Design ..................................................................................................24  
7.1.1.  Screening (Study Day -21 to -1) .................................................................................24  
7.1.2.  Treatment Period (Week 1 to Week 25)  .....................................................................25  
7.1.3.  Iron Absorption Substudy (See Table 3) ....................................................................[ADDRESS_808819]- Treatment / Early Termination Safety Follow -Up (Week 29) ...........................[ADDRESS_808820] Therapeutics, Inc. 
Protocol Amendment 3 â€“ [ADDRESS_808821] Withdrawal Criteria  .......................................................................................31  
9. STUDY PROCEDURES  ............................................................................................31  
10. TREATMENT OF SUBJECTS  ..................................................................................36  
10.1.  Description of Study Drug ..........................................................................................36  
10.2.  Concomitant Medications ...........................................................................................36  
10.2.1.  Contraceptive Requirements  .......................................................................................36  
10.3.  Treatment Compliance  ................................................................................................36  
10.4.  Randomization and Blinding ......................................................................................37  
11. STUDY DRUG MATERIALS AND MANAGEMENT  ...........................................38  
11.1.  PTG -300 .....................................................................................................................38  
11.1.1.  Study Drug ..................................................................................................................38  
11.1.2.  Study Drug Packaging and Labeling ..........................................................................38  
11.1.3.  Study Drug Storage .....................................................................................................38  
11.1.4.  Study Drug Administration.........................................................................................38  
11.1.5.  Study Drug Accountability .........................................................................................38  
11.1.6.  Study Drug Handling and Disposal ............................................................................39  
11.2.  57Fe Ferrous Sulfate Solution......................................................................................39  
12. ASSESSMENT OF EFFICACY  ................................................................................40  
12.1.  Clinical Endpoints ......................................................................................................40  
12.1.1.  Phlebotomy and Iron Parameters ................................................................................40  
12.1.2.  Iron Absorption (Iron Absorption Substudy) .............................................................40  
12.2.  Quality of Life Instruments  ........................................................................................40  
12.2.1.  Medical Outcome Study Questionnaire Short Form Health Survey (SF-36) .............40  
12.2.2.  Patient Global Impression of Change (PGI- C) ...........................................................40  
12.3.  Anti-Drug Antibodies (ADA) .....................................................................................[ADDRESS_808822] Therapeutics, Inc. 
Protocol Amendment 3 â€“ [ADDRESS_808823]  ...................................................................................................42  
13.3.  Pharmacokinetic Blood Sample Collection and Processing .......................................42  
14. ASSESSMENT OF SAFETY  .....................................................................................43  
14.1.  Safety Parameters  .......................................................................................................43  
14.2.  Adverse Events and Serious Adverse Events .............................................................43  
14.2.1.  Definition of Adverse Event .......................................................................................43  
14.2.2.  Definition of Serious Adverse Event ..........................................................................45  
14.2.3.  Pregnancy  ...................................................................................................................45  
14.2.4.  Other Safety Parameters and Related Information  .....................................................46  
14.3.  Recording Adverse Events .........................................................................................46  
14.4.  Reporting Adverse Events ..........................................................................................46  
14.5.  Follow-Up of Adverse Events and Serious Adverse Events ......................................47  
15. STATISTICS  ..............................................................................................................48  
15.1.  Study Design and Sample Size Estimation  .................................................................48  
15.2.  Demographics/Baseline Comparability  ......................................................................[ADDRESS_808824] (IRB) Approval ...............................................................[ADDRESS_808825] Therapeutics, Inc. 
Protocol Amendment 3 â€“ [ADDRESS_808826] of the Study ......................................................................................52  
16.5.3.  Written Informed Consent ..........................................................................................52  
16.6.  Termination of Study ..................................................................................................52  
16.7.  Case Report Forms  .....................................................................................................52  
16.8.  Inspection of Records .................................................................................................53  
16.9.  Retention of Records ..................................................................................................53  
17. PUBLICATION POLICY ..........................................................................................54  
18. REFERENCES  ...........................................................................................................55  
19. APPENDICES  ............................................................................................................56  
APPENDIX 1.  CLINICAL LABORATORY TESTS  ................................................................57  
APPENDIX 2.  ADDITIONAL LABORATORY TESTS  ..........................................................59  
APPENDIX 3.  MEDICAL OUTCOME STUDY QUESTIONNAIRE SHORT FORM  
HEALTH SURVEY (SF -36) ......................................................................................60  
APPENDIX 4.  PATIENT GLOBAL IMPRESSION OF CHANGE (PGI -C)............................[ADDRESS_808827] OF TABLES  
Table 1:  Abbreviations and Specialist Terms ...........................................................................15  
Table 2:  Schedule of Assessments for Study PTG-300-06 .......................................................32  
Table 3:  Schedule of Assessments for Study PTG-300-06 â€” Iron Absorption 
Substudy (Parts A and B) ...........................................................................................[ADDRESS_808828] Therapeutics, Inc. 
Protocol Amendment 3 â€“ [ADDRESS_808829] terms are used in this study protocol. 
Table 1: Abbreviations and Special ist T erms  
Abbreviation or Specialist Term  Explanation 
ADA  Anti-drug antibody 
AE Adverse event 
ALP  Alkaline phosphatase  
ALT  Alanine aminotransferase  
ANOVA  Analysis of variance 
AST  Aspartate aminotransferase  
AUC  Area under the curve  
BUN  Blood urea nitrogen 
CBC Complete blood count 
Cmax Maximum concentration 
CRA  Clinical research associate  
CRF  Case report form  
CRP  C-reactive protein  
CTCAE  Common Terminology Criteria for Adverse Events 
CTFG  Clinical Trials Facilitation Group  
DCIS  Ductal carcinoma in situ  
DLT  Dose- limiting toxicity  
ECG  Electrocardiogram  
eCRF  Electronic case report form  
eGFR  Estimated glomerular filtration rate  
EOS  End of study 
EOT  End of treatment  
FDA Food and Drug Administration 
FIH First in human  
GCP  Good Clinical Practice  
GLP  Good Laboratory Practice  
HBsAg  Hepatitis B  surface antigen  
Hct Hematocrit  
Protocol Number PTG-300-[ADDRESS_808830] Therapeutics, Inc. 
Protocol Amendment 3 â€“ [ADDRESS_808831] level  
PD Pharmacodynamic(s)  
PE Physical examination  
PI [INVESTIGATOR_609984]-C Patientâ€™s Global Impression of Change 
PK Pharmacokinetic(s)  
PRO Patient reported outcomes  
RBC Red blood cell 
RNA  Ribonucleic acid  
QoL Quality of life  
SAD Single ascending dose 
SAE  Serious adverse event  
SAP Statistical analysis plan  
SAR  Serious adverse reaction  
SC Subcutaneous 
SF-[ADDRESS_808832] Therapeutics, Inc. 
Protocol Amendment 3 â€“ [ADDRESS_808833] Therapeutics, Inc. 
Protocol Amendment 3 â€“ [ADDRESS_808834] Therapeutics, Inc. (Protagonist) is developi[INVESTIGATOR_609985]-300, an injectable peptide 
mimetic of the endogenous hormone hepcidin, as a potential treatment for hereditary 
hemochromatosis ( HH). 
HH is a  rare genetic disorder that disrupts the bodyâ€™s regulation of iron, caus ing the body to 
absorb too much iron from the diet. In HH types I-III, mutations in genes encoding hepcidin 
regulators, or hepcidin itself lead to diminished production of hepcidin, thus decreasing the 
inhibitory effect of hepcidin on duodenal iron absorption and causing clinical iron overload (Brissot 2011). Hepcidin deficiency  lead s to increased circulating transferrin saturation, and 
ultimately, iron accumulation in organs such as the liver, pancreas, heart, and bone. Iron in excess may induce or favor the development of complications such as cirrhosis, liver cancer, diabetes, heart failure, hypogonadism, but also, complaints such as asthenia and disabling 
arthritis.  If left untreated, HH can lead to morbidity and eventually death ( Katsarou 2019).  
Therapeutic phlebotomy to reduce iron loading is standard treatment for HH. The phlebotomy 
frequency required for a patient is based on serial measurements of their serum ferritin  levels and 
transferrin saturation ( Crownover 2013) . Therapeutic phlebotomy is highly efficient in removing 
excess iron and preventing most of the complications associated with excess iron in the body. However, this treatment does not target the biological mechanisms involved in the iron metabolism disturbance.  
In a hepcidin- deficient mouse model of hemochromatosis, a minihepcidin was effective for 
decreasing iron loading in the liver and heart compared to solvent control in mice that were not 
iron overloaded ( Ramos 2012). These observations suggest t hat a hepcidin mimetic such as 
PTG -300 may be effective for preventing iron overload in patients with hemochromatosis. 
5.1.1. Rationale for the Development of PTG-300 
PTG -300 is a peptidic agent structurally related to natural hepcidin that mimics its inhibitory 
activity on ferroportin. Hepcidin is a peptide hormone that is the bodyâ€™s main regulator of iron 
homeostasis ( Liu 2016, Ruchala 2014). Hepcidin binds to ferroportin causing internalization and 
degradation of ferroportin. Hepcidin binding to ferroportin on enterocytes blocks iron absorption 
from the gastrointestinal tract. The inhibitory effect of hepcidin on ferroportin in macrophages 
and hepatocytes leads to a decrease in the efflux of iron from t hese cellular sites of iron storage 
(Camaschella 2013 ). Because there are no mechanisms for the efflux of iron from cells other 
than ferroportin, and because iron is both essential and (in excess) toxic, the role of hepcidin is of central importance to iron regulation and erythropoiesis. Hepcidinâ€™s critical role in iron metabolism suggests that hepcidin mimetics such as PTG-300 may be effective for treating a 
variety of conditions characterized by [CONTACT_609994]. The rationale for testing PTG -300 in patients with HH is based on its potential ability to restore normal hepcidin function 
in patients with HH and thereby [CONTACT_609995]. 
The overall goal of the current protocol is to evaluate the safety and efficacy of PTG -300 in  
reducing phlebotomy requirement in patients with HH. The protocol is a Phase 2, single- arm, 
open- label  study (with an iron absorption substudy). 
Protocol Number PTG-300-[ADDRESS_808835] Therapeutics, Inc. 
Protocol Amendment 3 â€“ 14 September  2020 
CONFIDENTIAL AND PROPRIETARY  19 of 67 The study will be conducted in compliance with the protocol, Good Clinical Practice ( GCP ) 
guidelines, and applicable regulatory requirements. 
5.2. Summary of Nonclinical and Clinical Studies  
5.2.1. Nonclinical S tudies  
PTG -300 is a peptidic agent structurally related to natural hepcidin and PTG-300â€™s effects in 
toxicology studies mimic the effects of hepcidin. In studies of wild type mice, rats and 
cynomolgus monkeys, single dose subcutaneous or intravenous administration of PTG-[ADDRESS_808836] on serum iron is brisk in onset (within a few 
hours of subcutaneous dosing in the thalassemic mouse model) and, depending on the dose, can 
be quite profound and prolonged. For example, in wild type healthy mice, the ef fect of a 
2.5 mg/kg subcutaneous dose on serum iron persists for at least 30 hours with serum iron 
declining to a nadir (90% reduction) 10 hours after dosing. 
PTG -300 was evaluated in a comprehensive toxicology program including Good Laboratory 
Practice (G LP)-compliant studies. Specific GLP studies included up to 26-week rat and up to 
39-week cynomolgus monkey toxicology studies with 4- week or 5 -week reversal periods, as 
well as genetic toxicology studies to assess potential in vitro  mutagenesis, in vitro  chromosomal 
aberrations, and in vivo chromosomal aberrations. Safety pharmacology studies included hERG 
assay and i n vivo studies to assess potential effects on cardiovascular, respi[INVESTIGATOR_696] , and 
neurobehavioral parameters.  
In toxicology studies, PTG-300 caus es exaggerated pharmacological responses in rat s and 
cynomolgus monkeys when dosed for up to 26 or 39 weekly doses. The primary effects of 
PTG -300 in rats and cynomolgus monkeys are decreases in red blood cell count, hematocrit, and 
hemoglobin (Hgb) with e ither compensatory increases of reticulocyte counts at lower doses of 
PTG -300 or decreases of reticulocyte counts at high doses of PTG-300. Rats dosed with 
25 mg/kg PTG- [ADDRESS_808837], as well as hepatocellular necrosis that could be secondary to excess iron in 
liver. Rats dosed with 10 mg/kg/dose for [ADDRESS_808838] level ( NOAEL ) was 
determined to be 10 mg/kg/dose based on a 26- week  toxicology study in rats receiving weekly 
doses of PTG-300 of up to 10 mg/kg/dose. Cynomolgus monkeys dosed with 10 mg/kg PTG-[ADDRESS_808839]. 
Cynomolgus monkeys dosed with 6 mg/kg/dose for 13 weeks had no- adverse effects consistent 
with the expected pharmacology of PTG-300. The NOAEL was determined to be 2 mg/kg/dose 
following 39 weekly doses of PTG-300 at 0.6, 2, and 6 mg/kg/dose in cynomolgus monkeys. 
PTG -300 does not cause adverse injection site reactions in rats dosed up to 26 weeks or 
cynomolgus monkeys dosed up to 39 weeks. In a stand -alone single- dose rat local tolerance 
study with PTG-300 up to 280 mg/kg (280 mg/mL in dose concentration), the incidence and severity of injection site reactions were generally proportional to the dose and showed incomplete but progressive ongoing reversal by [CONTACT_995] [ADDRESS_808840] Therapeutics, Inc. 
Protocol Amendment 3 â€“ 14 September  2020 
CONFIDENTIAL AND PROPRIETARY  20 of 67  
PTG -300 was also evaluated for embryo-fetal development toxicity in rats and rabbits and 
fertility and early embryonic development toxicity in both male and female rats. The maternal 
NOAEL was 3 mg/kg/dose and the NOAEL for the embryo- fetal development was 
0.3 mg/kg/dose in the definitive embryo- fetal development toxicity study in rats. The maternal 
NOAEL was 1 mg/kg/dose and the NOAEL for the embryo- fetal development was 
0.3 mg/kg/dose in the definitive embryo- fetal development toxicity study in  rabbits. The NOAEL 
for paternal toxicity and the NOEL for effects on male fertility and early embryonic development were considered to be 10 mg/kg/dose in fertility and early embryonic development toxicity study in male rats. The NOAEL for maternal toxicity and the NOEL for effects on female fertility and 
early embryonic development were 3 mg/kg/dose in fertility and early embryonic development 
toxicity study in female rats.  
Principle findings in nonclinical toxicology studies are alterations in red cell m ass. PTG -[ADDRESS_808841] on cardiovascular, respi[INVESTIGATOR_696], or neurobehavior in safety pharmacology studies. PTG-300 is not genotoxic. 
5.2.2. Clinical S tudies  
To date, PTG-300 has been studied in one completed Phase 1 study in healthy subjects. A 
Phase 2 study of PTG -300 and the studyâ€™s open -label extension for treatment of Î² -thalassemia 
investigat ed doses over a range of [ADDRESS_808842] adverse events were typi[INVESTIGATOR_609986] Î² -thalassemia. The frequency of adverse 
events did not increase with increasing dose of PTG-300. Adverse events reported in >5% of subjects were upper respi[INVESTIGATOR_1092] (11.1%), injection site erythema (9.5%), injection site pain (12.7%), urinary tract infections (7.9%), headache (7.9%), fatigue (6.3%), and pyrexia 
(6.3%). One subject experienced an SAE of confusion, which was considered by [CONTACT_609996]-300. The event fully resolved within [ADDRESS_808843]- in-human 
(FIH), single ascending dose (SAD) and repeat dose study of PTG-300 administered subcutaneously ( SC) in 62 healthy male subjects to evaluate safety/tolerability, PK and PD 
activity (as assessed by [CONTACT_609997]).  Subjects received single doses of 
1 mg to 80 mg PTG -300 or two 40 mg doses 1 week apart.  
Following single dose administration of PTG-300 there was a dose-related reduction in serum 
iron with a maximal reduction of approximately 65% from baseline. The relationship between 
dose and effect appeared to plateau at [ADDRESS_808844] 72  hours at higher doses. In subjects that received 
two 40- mg doses 1 week apart (QWÃ—2) the effects on iron were comparable for both 40-mg 
Protocol Number PTG-300-[ADDRESS_808845] Therapeutics, Inc. 
Protocol Amendment 3 â€“ 14 September  2020 
CONFIDENTIAL AND PROPRIETARY  21 of 67 doses. Serum iron levels did not return to baseline prior to the second dose. Serum iron levels 
generally returned to baseline approximately 1 to 2 weeks following the second dose of 
PTG -300. Following single dose administration area under the concentration -time curve ( AUC ) 
and maximum concentration (C max) increased  with dose; however, the increase was less than 
dose-proportional. 
PTG -300 was well tolerated  by [CONTACT_117954], with no SAEs or dose- limiting toxicities 
(DLTs) at single doses as high as [ADDRESS_808846] frequent advers e events ( AEs) were injection site reactions (characterized primarily by a 
transient erythema at the injection site), headaches and upper respi[INVESTIGATOR_6014]. 
These preclinical and clinical data support clinical development of PTG-[ADDRESS_808847] s with HH who are in maintenance phase and who are on a stable 
phlebotomy regimen. 
5.4. Selection of Doses  
Subjects will initially  receive a subcutaneous dose of 10 mg per week . The dose was based on 
data in healthy subjects indicating that a dose of 10 mg PTG-300 results in an average reduction 
of approximately 19% in serum iron. Iron levels returned to baseline within [ADDRESS_808848]â€™s dose may be increased to [ADDRESS_808849] 3 days apart (e.g ., on Day 1 and Day 4 or 5 of each week) .
 The intent of 
dose and schedule adjustment is to reduce TSAT and serum iron levels. These higher doses are 
based on Phase 1 data that showed greater decreases in serum iron and TSAT and longer 
duration of decrease compared to the 10 mg dose. A Safety Monitoring Committee (SMC) has 
determined that doses as high as [ADDRESS_808850] not been observed in nonclinical 
species, however administration of PTG -300 carries theoretical liabilities (immunologically  
Protocol Number PTG-300-[ADDRESS_808851] Therapeutics, Inc. 
Protocol Amendment 3 â€“ 14 September  2020 
CONFIDENTIAL AND PROPRIETARY  22 of 67 based responses) associated with the systemic administration of a peptide. In the Phase 1 study 
PTG -300 was well tolerated, with the majority of AEs other than injection site reactions 
(primarily transient erythema) considered to be unrelated to PTG-300. In two ongoing Phase [ADDRESS_808852] s will receive an oral administration of approximately 4 mg 57Fe as a 
ferrous sulfate solution. Stable isotopes are non- radioactive atoms of the same chemical element, 
which differ only in their number of neutrons ( Bodamer 2001).  Such studies are common in 
nutrition science and are often conducted to examine the absorption of selected elements (e.g., 
iron) from various foods and the impact of various diseases. These tracers are considered safe 
and may be particularly important for the validation of new treatment modalities, such as novel drug treatmen ts (Bodamer 2001). 
Protocol Number PTG-300-[ADDRESS_808853] Therapeutics, Inc. 
Protocol Amendment 3 â€“ 14 September  2020 
CONFIDENTIAL AND PROPRIETARY  23 of 67 6. OBJECTIVES 
The study objectives are as follows: 
1. To assess the safety and tolerability of PTG -[ADDRESS_808854] of PTG -300 therapy on transferrin saturation (TSAT) and serum 
ferritin . 
3. To assess the effect of PTG -300 on iron absorption in a subset of subjects. (For subjects 
participating in the iron absorption substudy). 
4. To assess PTG -300â€™s efficacy for treating HH subjects as defined by [CONTACT_609998]. 
5. To assess the effect of PTG -300 on quality of life (QoL). 
6. To assess the pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of 
PTG -300. 
Protocol Number PTG-300-[ADDRESS_808855] Therapeutics, Inc. 
Protocol Amendment 3 â€“ 14 September  2020 
CONFIDENTIAL AND PROPRIETARY  24 of 67 7. INVESTIGATIONAL PLAN 
7.1. Overall Study Design  
This is a multicenter, single -arm, open-label study in subjects with HH. Subjects will receive 
subcutaneous PTG-300 for up to 24 weeks. Subjects will start at an initial dose of 10 mg per 
week subcutaneously. The dose may be increased to 20 mg per week, and subsequently to 40 mg 
and to 80 mg per week if needed, based on tolerability and the pharmacodynamic marker TSAT. In addition, subcutaneous dosing schedules of 10 mg, 20 mg, and 40 mg twice weekly (Day 1 
and either Day 4 or Day 5) may be tested. 
Based on a review of the TSAT and safety data from at least the first 4 subjects, the starting dose 
and/or the dosing regimen may be modified for subsequent subjects to reduce exposure to 
ineffective doses. 
Subjectsâ€™ safety and blood iron parameters ( serum iron, serum ferritin, transferrin, and TSAT)
 
will be collected  to monitor the pharmacodynamic effect of PTG -300. Effect on phlebotomy 
need and quality of life ( QoL) data ( 36-Item Short Form Health Survey [ SF-36], and Patientâ€™s 
Global Impression of Change [ PGI-C]) will also be collected and tabulated.  
A subset of subjects (approximately 6 subjects ) will participate in a sequential two -way 
crossover iron (57Fe) absorption substudy. The oral iron absorption substudy will be conducted 
once during the 3- week screening period  and then following approximately 4 to 6 weeks of 
PTG -300 treatment.  
Subjects will participate in this study for up to 3 1 weeks as follows:  
â€¢ Screening: Up to 3 weeks  
â€¢ PTG -300 Treatment: Up to 24 weeks (may include iron absorption substudy for 
selected subjects)  
â€¢ Safety follow up: 4 weeks. 
7.1.1. Screening (Study D ay -21 to -1) 
After giving written informed consent, subjects will be screened for eligibility according to 
inclusion/exclusion criteria ( see Section  8) within 21 days of dosing. Subjects will continue their 
individual iron restricted diet throughout the study. During this period liver iron concentration (LIC) will be assessed by [CONTACT_9252] (MRI). Subjects will begin treatment with PTG -300 within approximately 7 days following a regular phlebotomy, with iron parameters 
measured before (Screening labs) and after the phlebotomy (pre -dose Study Day 1). E ach 
individual subjectâ€™s pre- phlebotomy serum ferritin level and TSAT will be used as a criterion for 
phlebotomy during the study, i.e., the threshold at which a phlebotomy should be considered 
during the study. The serum ferritin level and TSAT obtained during Screening will be used as 
baseline to assess the change from these measurements post -dosing with PTG-300. All 
concomitant medications received by [CONTACT_609999] [ADDRESS_808856] Therapeutics, Inc. 
Protocol Amendment 3 â€“ 14 September  2020 
CONFIDENTIAL AND PROPRIETARY  25 of 67 After eligibility has been confirmed, subjects will be enrolle d in the study. Those subjects who 
choose to participate and complete informed consent for the iron absorption substudy will 
complete their Iron Absorption A session during Screening ( See Section  7.1.3 below). 
7.1.2. Treatment Period (Week 1 to Week 25) 
Study Drug Administration: Dosing with PTG-[ADDRESS_808857] subcutaneous (SC) injection at the clinic and will be instructed on how to self-administer the injection (or have a caregiver administer the injection) and on appropriate safety monitoring before being discharged. 
On Study Day 2, subjects will return to the clinic for serum iron parameters and PTG-300 blood concentration (PK) measurements.  
Individual Subject Dose and Schedule Escalation : Individual subject dose and schedule will be 
determined based on the pharmacodynamic (PD) marker TSAT measured at two time points: once at peak PD effect one day post dose and once at trough PD effect. The intent of dose and schedule adjustment is to reduce TSAT and serum iron levels. The dose of PTG-300 may be 
increased weekly in a sequential manner from 10 mg to 20 mg and, if necessary, to 40 mg and 
80 mg until the TSAT is less than approximately
 40% at peak PD effect one day post dose and at 
the trough PD  effect prior to the next dos e of PTG -300. In addition, the dose may be adjusted to 
maintain serum ferritin to no more than 1.5 times the screening value or 150 ng/mL, whichever is greater. Investigators may consider once a week or twice a week dosing of PTG-[ADDRESS_808858] is the TSAT value measured 7 days after the PTG -300 
dose (and before the next dose) for once weekly dosing or [ADDRESS_808859] 3 days 
apart (e.g., on Day 1 and Day 4 or 5 of each week ). The twice weekly PTG -300 dose may be 
escalated to a maximum of 40 mg twice weekly. To facilitate dose escalation and the identification of a therapeutic dose, investigators may assess TSAT values on days subjects come to the clinic for any dose adjustments. These assessments may occur at times other than the regular scheduled visits indicated on the schedule of events. 
Subjects will continue treatment by [CONTACT_6270] -administering PTG -300 at home (or in the clinical center 
as appropriate) for up to 24 weeks based on acceptable safety and tolerability of the drug 
(Section  7.2). Subjects will return for clinic visits to have safety assessments; serum iron 
parameters plus  soluble transferrin receptor  (sTfR), hepcidin and antidrug antibodies (ADA); and 
efficacy evaluated according to the schedule of assessments.  
Subjectsâ€™ iron parameters will be monitored throughout the study. 
Change in S tarting Dose: The starting dose may be increased from 10 mg to 20 mg, 40 mg, or 
80 mg as appropriate if <[ADDRESS_808860] 4 subjects (o r â‰¤25% of a larger number of subjects) treated 
at a given dose have both peak and trough TSAT values approximately <40% and no safety 
signals have been noted. 
Protocol Number PTG-300-[ADDRESS_808861] Therapeutics, Inc. 
Protocol Amendment 3 â€“ 14 September  2020 
CONFIDENTIAL AND PROPRIETARY  26 of 67 Criteria for a Phlebotomy: Subjects should undergo an on-study phlebotomy when the subjectâ€™s 
serum ferritin levels and TSAT value are higher than the pre-phlebotomy serum ferritin and 
TSAT values obtained during Screening. In addition, a phlebotomy may be performed when the Investigator assesses it is necessary for subj ect care.  
7.1.3. Iron Absorption Substudy  (See Table 3 ) 
Iron absorption subjects will be treated and monitored in an identical manner as the rest of the study population. 
Subjects consenting to participate in the iron absorption substudy will receive the stable iron 
isotope 
57Fe orally (approximately 4 mg as ferrous sulfate ) on two occasions; once prior to 
starting PTG -300 (i.e., after the phlebotomy perfo rmed during the Screening period, Iron 
Absorption A), and a second dose after 4 to 6 weeks after starting PTG -300 (i.e., post- treatment; 
Iron Absorption B).  The post -treatment Iron Absorption B administration will occur 
approximately [ADDRESS_808862] 
for approximately 4 hours after the 57Fe do se. Blood samples will be collected at 0, 4, 8, 12, and 
24 hours for measurement of 57Fe levels  and for measurement of iron parameters â€”serum iron, 
serum ferritin, transferrin, and TSA T. Additional blood samples wi ll be obtained at 0, 4, 8, 12, 
and [ADDRESS_808863] 12 hours, after which subjects may stay overnight or be discharged 
home (at the discretion of the subject and investigator) and return the next day (approximately 
24 hours following 57Fe administration).  
7.1.4. Post-Treatment / Early Termination Safety Follow-Up (Week 29) 
Subjects w ho complete the treatment or who discontinue treatment early will undergo Visit 8/end 
of treatment (EOT) assessments as well as f ollow-up safety evaluations approximately [ADDRESS_808864] dose of study drug (Visit 9/end of study [EOS]). 
7.2. Safety 
Safety will be monitored carefully throughout the study. 
Safety measures ( including but not limited to physical examinations, clinical laboratory tests , 
complete blood count [ CBC], vital signs, electrocardiograms [ ECGs ], adverse event monitoring 
[AEs], and concom itant medications) will be evaluated and recorded over the course of the study 
according to the schedule of assessments ( Table 2 ). Clinical sites may co nduct local laboratory 
tests if required by [CONTACT_100412]. 
Any AE that emerges from the time th e subject signs an informed consent form (ICF) until Study 
Exit will be recorded and reported. Safety will be assessed using National Institutes of Health 
(NIH) Common Terminology Criteria for Adverse Events ( CTCAE ) v5.[ADDRESS_808865] Therapeutics, Inc. 
Protocol Amendment 3 â€“ [ADDRESS_808866] one of the following criteria will require  a dose reduction: 
â€¢ CTCAE Gr ade 3 hematological toxicity or worsening of â‰¥2 grades in hematological 
parameters not clearly resulting from the underlying disease and/or without a clear-
cut alternative that does not respond adequately to medical therapy. 
â€¢ CTCAE Grade 3 non- hematological toxicities not clearly resulting from the 
underlying disease and/or without a clear-cut alternative that does not respond adequately to medical therapy. 
â€¢ Treatment -related decrease of Hgb from baseline >20% or G rade 2 anemia, 
whichever is lesser, confirmed  by a repeat value and not due to phlebotomy. Prior to 
resumption of PTG-300 at a reduced dose a follow-up Hgb should be assessed to confirm that Hgb has stabilized or improved to Grade 1. 
â€¢ Investigator determines that the subject has experienced a clinical ly significant 
decrease in Hgb due to PTG-300. 
If a treatment- related  increase in aspartate aminotransferase (AST) or alanine aminotransferase 
(ALT) >3 Ã— upper limit of normal (ULN) is seen, dosing with PTG-[ADDRESS_808867] and/or ALT levels return to baseline within 14 days; if 
the levels do not return to baseline within [ADDRESS_808868] from further treatment with study drug: 
â€¢ Any CTCAE Grade 4 hematological or non- hematological toxicity  not clearly 
resulting from the underlying disease and/or without a clear- cut alternative . 
â€¢ CTCAE Grade 3 hematological toxicity or worsening of â‰¥2 grades in hematological 
parameters not clearly resulting from the underlying disease and/or without a clear-cut alternative persists over 7 days after adequate PTG -300 dose decrease. 
â€¢ CTCAE Grade 3 non- hematological toxicities not clearly resulting from the 
underlying disease and/or without a clear- cut alternative explanation that do not 
improve within 14 days with maximal medical therapy and adequate PTG-300 dose decrease.  
â€¢ When the Investigator in consultation with the medical mo nitor ( MM) considers that 
is in the subjectâ€™s best interest to discontinue treatment with PTG -300 (i.e., persistent, 
worsening or recurrent AEs). 
â€¢ If a subject requires a dose reduction below [ADDRESS_808869] Therapeutics, Inc. 
Protocol Amendment 3 â€“ 14 September  2020 
CONFIDENTIAL AND PROPRIETARY  28 of 67 â€¢ ALT, AST >5 Ã— ULN and rising . 
â€¢ ALT, AST remains >5 Ã— ULN with no change in total bilirubin for more than 
2 weeks . 
â€¢ A worsening of clinical symptoms with no other acceptable explanation. 
â€¢ The product meets Hyâ€™s Law: 
âˆ’ Any test showing an increase of serum ALT >3 Ã— ULN or >2 Ã— ULN total 
bilirubin should be repeated within [ADDRESS_808870], alkaline phosphatase (ALP), and total bilirubin . If the repeat value for ALT or total 
bilirubin  is unchanged or indicates decreasing activity, monitoring should 
continue at weekly intervals until the results are accep table or normalized . 
â€¢ Evidence of clinically meaningful increased iron accumulation in liver from baseline. 
7.3. Number of Subjects  
Approximately [ADDRESS_808871]â€™s dose up to 80 mg per week  based on lack of 
pharmacodynamic (TSAT)  response and acceptable safety . The  starting dose and/or the dosing 
regimen will be evaluated and modified to enhance clinical benefit ( see Section  7.1.2).  
Based on pre- defined safety criteria (see Section  7.2.1), a subjectâ€™s dosing frequency and dose 
may be reduced . 
7.6. Endpoints  
Baseline  Definition: The serum ferritin level and TSAT obtained during Screening will be used 
as baseline.  
7.6.1. Efficacy  
â€¢ Change from baseline in serum ferritin.  
â€¢ Duration of time that serum ferritin is below baseline measurement . 
â€¢ Change from baseline in TSAT.  
â€¢ Duration of time that TSAT is belo w baseline measurement . 
â€¢ Time to first phlebotomy  after dosing. 
Protocol Number PTG-300-[ADDRESS_808872] Therapeutics, Inc. 
Protocol Amendment 3 â€“ 14 September  2020 
CONFIDENTIAL AND PROPRIETARY  29 of 67 â€¢ Change in frequency of phlebotomies based on historical phlebotomy data 
(24 weeks) . 
â€¢ Proportion of subjects who achieve phlebotomy independence. 
â€¢ Additional Endpoints: 
âˆ’ SF-36 
âˆ’ PGI-C 
âˆ’ Change in iron absorption following the administration of PTG-300. (For subjects 
complet ing iron absorption substudy.) 
âˆ’ PTG -300 pharmacokinetics: PTG-[ADDRESS_808873] dose.  
âˆ’ PD: Change from baseline in serum iron, transferrin and sTfR. 
âˆ’ Change from baseline in LIC assessed by [CONTACT_9268]. 
âˆ’ Incidence of ADA.  
7.6.2. Safety  
Safety is assessed using NIH CTCAE v5.0 criteria. 
â€¢ Tabulate frequency of treatment -emergent adverse events (TEAEs) and SAEs; 
treatment -related TEAEs and SAEs; TEAEs leading to study discontinuation. 
â€¢ Summarize vital signs, safety laboratory assessments, ECGs, and physical examination findings. 
Protocol Number PTG-300-[ADDRESS_808874] Therapeutics, Inc. 
Protocol Amendment 3 â€“ [ADDRESS_808875] meet ALL of the following inclusion criteria to be enrolled:  
1. Male and female subjects aged [ADDRESS_808876] a confirm ed diagnosis of HFE- related hereditary hemochromatosis with prior 
genotype testing. 
3. Documented stable phlebotomy for â‰¥ 6 months prior to screening ; with a phlebotomy 
frequency of at least  0.25 per month ( e.g., received at least three phlebotomies over the 
previous [ADDRESS_808877] four phlebotomies over the previous 15 months) and a 
phlebotomy frequency of less than 1 per month. 
4. Screening hemoglobin >11.5 g/dL. 
5. Serum f erritin <300 ng/mL at screening (before screening phlebotomy). 
6. Women of childbearing potential (WOCBP) and men with partners of childbearing 
potential agree to use a highly effective contraceptive measure (based on the C linical 
Trials Facilitation Group [C TFG ]) during the duration of the study and for [ADDRESS_808878] meet NONE of the following exclusion criteria to be enrolled.  
1. Clinically meaningful laboratory abnormalities at Screening including, but not limited to: 
a. Absolute neutrophil count <1000/ÂµL 
b. Platelet count <100,000/ÂµL 
c. Estimated Glomerular Filtration Rate (eGFR) <40 mL/min/1.73 m2 
d. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) â‰¥2.5 Ã— 
upper limit of normal (ULN) or direct bilirubin >1.5 Ã— ULN 
e. C-react ive protein (CRP) â‰¥5.0 mg/L. 
2. Receiving iron chelation therapy. 
3. Receiving erythrocytapheresis . 
4. Pregnant or lactating females.  
5. Infection requiring hospi[INVESTIGATOR_609983], or opportunistic 
infection within 3 months of dosing; any infection requiring antimicrobial therapy within 
4 weeks of dosing. Prophylactic antibiotics are allowed. 
6. Any serious or unstable medical or psychiatric condition that would prevent (as judged 
by [CONTACT_737]) the subject from properly providing informed consent or any 
Protocol Number PTG-300-[ADDRESS_808879] Therapeutics, Inc. 
Protocol Amendment 3 â€“ 14 September  2020 
CONFIDENTIAL AND PROPRIETARY  31 of 67 condition which would jeopardize compliance with the study or assessment of the studyâ€™s 
endpoints. 
7. Organ damage from iron overload, that (as judged by [CONTACT_737]) may be worsened 
by [CONTACT_609992].  
8. Known primary or secondary immunodeficiency. 
9. Known history of autoimmune/inflammatory diseases. 
10. Positive for active hepatitis B or hepatitis C or known human immunodeficiency virus 
(HIV) infection. Active hepatitis B is defined as a known positive hepatitis B  surface 
antigen  (HBsAg) result. Active hepatitis C is defined by a positive  hep C Ab result and 
known quantitative hepatitis C virus (HCV) ribonucleic acid  (RNA) results greater than 
the lower level of detection of the assay. Subjects who have a history of HCV infection but have documented sustained virologic response 12 weeks after HCV therapy (SVR12) are eligible . 
11. Any surgical procedure requiring general anesthesia within 1 month prior to screening or planned elective surgery during the study (within 3 months for joint replacement surgery).  
12. History of invasive malignancies within the last 2 years, except non- melanoma skin 
cancer and localized cured prostate cancer, cervical cancer, and ductal carcinoma in situ (DCIS).  
13. Current or recent history of alcohol dependence or illicit drug use within [ADDRESS_808880]â€™s 
best interest.  
A subject must be withdrawn if the subject becomes pregnant, is non-compliant with study procedures so that assessment of safety and efficacy are significantly co mpromised, starts an 
experimental therapy for HH, or meets dose stoppi[INVESTIGATOR_3418] ( Section  7.2.2).  
9. STUDY PROCEDURES  
Study procedures should be completed as designated in the Schedules of Assessments ( Table 2  
and Table 3 ). 
Protocol Number PTG-300-[ADDRESS_808881] Therapeutics, Inc. 
Protocol Amendment 3 â€“ 14 September  2020 
CONFIDENTIAL AND PROPRIETARY  32 of 67 Table 2: Schedule of Assessments for Study PTG -300-06 
Assessment  Screeninga 24 Weeks of PTG-300 Treatment Visit 9/EOS  
Safety 
Follow -Up 
Study W eekb D -21 to -1  Visit 1 
(Wk 1)  Visit 2 
(Wk 3 
[D15]) Visit 3 
(Wk 5 
[D29]) Visit 4 
(Wk 9 
[D57]) Visit 5 
(Wk 13 
[D85]) Visit 6 
(Wk 17 
[D113]) Visit 7 
(Wk 21 
[D141]) Visit 
8/EOT  
(Wk 25 
[D169]) ~[ADDRESS_808882] 
Dosec 
(~Wk 29) D1 D2 
Informed Consent & HIPAA 
Authorizationd X           
Significant m edical history  X           
Phlebotomy  history (for up to 
previous 15 months)  X           
Inclusion/exclusion c riteria  X           
Demographics  X           
Physical examination (including 
weight) X          X 
Height  X           
Vital signs  X X X  X X X X X X X 
12-lead ECG  X X X   X  X  X X 
MRI (liver iron con centration ) X         X  
Hepatitis B & C screen  X           
Phlebotomy  Xe           
Phlebotomy evaluationf     X X X X X X  
Concomitant medications  X X   X X X X X X X 
Adverse eventsg X X X X X X X X X X X 
Serum pregnancy testh X          X 
Urine pregnancy testh  
X   X X X X X X  
CRP  X     X  X  X  
Protocol Number PTG-300-[ADDRESS_808883] Therapeutics, Inc. 
Protocol Amendment 3 â€“ 14 September  2020 
CONFIDENTIAL AND PROPRIETARY  33 of 67 Assessment  Screeninga 24 Weeks of PTG-300 Treatment Visit 9/EOS  
Safety 
Follow -Up 
Study W eekb D -21 to -1  Visit 1 
(Wk 1)  Visit 2 
(Wk 3 
[D15]) Visit 3 
(Wk 5 
[D29]) Visit 4 
(Wk 9 
[D57]) Visit 5 
(Wk 13 
[D85]) Visit 6 
(Wk 17 
[D113]) Visit 7 
(Wk 21 
[D141]) Visit 
8/EOT  
(Wk 25 
[D169]) ~[ADDRESS_808884] 
Dosec 
(~Wk 29) D1 D2 
Iron Absorption Substudyi X    Xi       
Study drug administrationj  Weekly   
Clinical laboratory test sk X X   Xk X Xk X Xk X X 
CBC X X   X X X X X X X 
Iron parameters: Serum iron, 
transferrin saturation (TSAT ), 
serum ferritin, transferrinl,m X X X X X X X X X X  
Soluble transferrin receptor  
(sTfR)  X     X    X  
Hepcidin  X     X    X  
PK blood samples for 
measurement of PTG -300 
concentrationm  Xl X X X X Xl X X X X 
ADA   X    X  X  X X 
SF-36 X         X  
PGI-C      X  X  X  
Assess study drug compliance      X X X X X X  
Abbreviations: ADA = anti-drug antibody , CBC = complete blood count , CRP = C-reactive protein , D = day, ECG = electrocardiogram , EOS = end 
of study, EOT = end of treatment, HIPAA = Health Insurance Portability and Accountability Act , MRI = magnetic resonan ce imaging, PGI -C = 
Patientâ€™s Global Impression of Change , SF-36 = 36-Item Short Form Health Survey, sTfR = soluble transferrin receptor , TSAT = transferrin 
saturation.  
NOTE: Subjects may require additional visits one day post dose to assess PD effect  for dose escalation . 
a Subjects may be rescreened if necessary.  Rescreening is considered conducting screening tests outside of the 21 -day screening window . 
b Clinical visits should be conducted within an approximately 2- day window ( Â±2 days) . All study p rocedures should occur before study drug administration 
except as indicated (i .e., PK/PD) . 
Protocol Number PTG-300-[ADDRESS_808885] Therapeutics, Inc. 
Protocol Amendment 3 â€“ [ADDRESS_808886] completes the study or terminates  early . 
d Subjects enrolled at sites in the [LOCATION_002] (US) must sign HIPAA authorization prior to the conduct of any study- specific procedures.  
e Must be conducted within approximately [ADDRESS_808887] be collected before phlebotomy. Note: the pre -
phlebotomy serum ferritin level and TSAT will be used as the subjectâ€™s individual phlebotomy threshold for the study, i.e., t he designated level at which a 
phlebotomy will be considered.  
f If a subject meets pre -specified criteria for phlebotomy during a visit, schedule a phlebotomy as soon thereafter as possible.  
g Additional tests or examinations, including physical exams, may be conducted as necessary. 
h For women of childbearing potential onl y. 
i Iron Absorption A is conducted prior to starting PTG -300 (i.e., after the phlebotomy performed during the Screening period). Iron Absorption B should be 
conducted after approximately 4 to 6  weeks of PTG -300 treatment (one day after PTG -300 administration  between Week 4 and Week 6). See Table 3  for the 
Iron Absorption substudy schedule of events.  
j Study drug administration: PTG -[ADDRESS_808888] of clinical laboratory tests.  At Visits 3, 5, and 7 , tests will include chemistry and CBC panel only (no urinalysis).  
l These tests should be conducted every [ADDRESS_808889]â€™s dose  is escalated (See Section  13.1 and Appendix 2 ). Additional tests may be obtained as outlined in 
Individual Subject Dose and Schedule Escalation  in Section  7.1.2 . 
m All sample collection for iron parameters, PK (PTG -300 concentrations) are conducted pre -dose at each clinic visit, with additional [ADDRESS_808890] Therapeutics, Inc. 
Protocol Amendment 3 â€“ 14 September  2020 
CONFIDENTIAL AND PROPRIETARY  35 of 67  
Table 3: Schedule of Assessments for Study PTG -300-06 â€” Iron Absorption Substudy  (Part s A and B)  
Assessment  Hours Post 57Fe Dosing  
0 4 8 12 24 
57Fe administrationa X     
Iron parameters: Serum iron, serum ferritin, TSAT , 
transferrin  and 57Fe Xb X X X X 
PTG -300 concentrationc Xb X X X X 
Vital signs  X   X X 
Adverse events  X   X X 
Note: Iron Absorption A is conducted prior to starting PTG -300 (i.e., after the phlebotomy performed during the Screening period) . Iron Absorption B should 
be conducted after approximately 4 to 6 weeks of PTG -300 treatment (one day after PTG -300 administra tion between Week 4 and Week 6). 
Abbreviations: TSAT = transferrin saturation . 
a During Iron Absorption B, 57Fe should be administered approximately one day  after PTG -[ADDRESS_808891] Therapeutics, Inc. 
Protocol Amendment 3 â€“ 14 September  2020 
CONFIDENTIAL AND PROPRIETARY  36 of 67 10. TREATMENT OF SUBJECTS  
10.1. Description of Study Drug  
This study is a single- arm, open-label study; there is no placebo or comparator used. 
PTG -[ADDRESS_808892]. 
PTG -300 is formulated in an aqueous buffered solution and prefilled at 0.5 mL and 1.0 mL into a 
1-mL glass syringe. Study drug will be administered by [CONTACT_6567] (SC) injections, using a 
needle and a pre -filled syringe.  
57Fe will be provided by [CONTACT_610000] a ferrous sulfate solution for oral administration . 
10.2. Concomitant Medications  
Subjects must receive appropriate care for HH including phlebotomy. Subjects should receive full supportive care for any other underlying conditions and all medications taken are recorded . 
Investigational agents must have been discontinued at least [ADDRESS_808893] beginning 30 days 
prior to Screening should be collected.  
10.2.1. Contraceptive Requirements  
Women of childbearing potential (WOCBP) and men must use medically acceptable contraception (<1% annual failure rate) during the duration of the study and for [ADDRESS_808894] 
and/or partner include but are not limited to the following: 
â€¢ Combined (estrogen and progesterone containing) hormonal contraceptives (for at 
least 3 months before screening) (oral, intravaginal, or trans dermal)  
â€¢ Progesterone-only hormonal contraception (oral, injectable, or implantable) associated with inhibition of ovulation 
â€¢ Intrauterine device (IUD)  
â€¢ Intrauterine hormone- releasing system (IUS)  
â€¢ Surgically sterile ( e.g., vasectomy, hysterectomy, bilateral salpi[INVESTIGATOR_1656],  or bilateral 
oophorectomy at  least 3  months before dosing) 
â€¢ Sexual abstinence. 
10.3. Treatment Compliance  
Study drug accountability and reconciliation will be performed by [CONTACT_610001](s).  
Protocol Number PTG-300-[ADDRESS_808895] Therapeutics, Inc. 
Protocol Amendment 3 â€“ 14 September  2020 
CONFIDENTIAL AND PROPRIETARY  37 of 67 10.4. Randomization and Blinding  
This is a single -arm, open-label study; no randomization or blinding is used. 
Protocol Number PTG-300-[ADDRESS_808896] Therapeutics, Inc. 
Protocol Amendment 3 â€“ [ADDRESS_808897] be stored at 2 Â°C to 8Â°C, protected from light, in a locked area with 
limited access.  
Storage instructions are included on the label.  The Pharmacy Manual and Program Guide 
provide more detailed instructions on drug management. 11.1.4. Study Drug Administration 
Injection sites are SC tissue in the abdomen ([ADDRESS_808898] from the navel), triceps,  or thighs. 
Sites should be rotated between injections. 
Doses that are administered at the study site on clinic visit days will be given by a trained health 
care practitioner.  
All doses should be administered in the clinic until the subject or caregiver demonstrates the 
ability to successfully administer PTG -300. Additionally, study drug should be administered in 
the clinic whenever the subject is scheduled for a dose on a clinic visit day. 
11.1.5. Study Drug Accountability  
Compliance will be assessment  throughout the study. 
A record will be maintained by [CONTACT_610002]. 
Investigators will be fully responsible for the security, accessibility , and storage of the study drug 
while it is a t investigational sites. Investigators are also responsible for the education of study 
staff in the correct administration of the study drug. 
Protocol Number PTG-300-[ADDRESS_808899] Therapeutics, Inc. 
Protocol Amendment 3 â€“ [ADDRESS_808900] be supplied to the study monitor. 
Further information of the storage, handling and administration of study drug will be provided in 
the Pharmacy Manual.  
11.2. 57Fe Ferrous Sulfate Solution  
57Fe (approximately 4 mg) is provided by [CONTACT_610003]. 
Further information of the storage, handling, and administration of 57Fe will be provided in the 
Pharmacy Manual.  
Protocol Number PTG-300-[ADDRESS_808901] Therapeutics, Inc. 
Protocol Amendment 3 â€“ [ADDRESS_808902] â€™s phlebotomy will be based on their established TSAT and serum ferritin 
pre-phlebotomy threshold. 
During the screening phase, subjects will have a phlebotomy within  approximately [ADDRESS_808903]â€™s pre-phlebotomy serum  ferritin level will be used as 
their individual phlebotomy threshold, i.e., the designated level at which a phlebotomy may be performed  in the study. 
Subjectsâ€™ iron parameters will be monitored throughout the study. A subject will receive a therapeutic phlebotomy during the study if his/her TSAT  and serum ferritin is above their pre-
phlebotomy level at Screening. 
12.1.2. Iron Absorption (Iron Absorption Substudy)  
Subjects consenting to participate in the iron absorption substudy will have their iron absorption 
meas ured at two time points, pre- treatment with P TG-300 (Iron Absorption A) and after 
approximately 4 to 6 weeks of treatment with PTG -300 (Iron Absorption B). The purpose of the 
iron absorption substudy is to quantify the absorption of iron, marked by [CONTACT_941] 
57Fe isotope and the 
effect of PTG -300 on absorption of iron following oral dosing. 
12.2. Quality of Life Instruments  
12.2.1. Medical Outcome Study Questionnaire Short Form Health Survey (SF -36) 
The Medical Outcome Study Questionnaire Short Form Health Survey (SF-36;  Appendix 3) is a 
36-item short- form (SF -36) questionnaire constructed to survey health st atus in the Medical 
Outcomes Study (MOS) ( Ware 1992 ). The SF -36 includes one multi- item scale that assesses  
eight health concepts: 1) limitations in physical activities because of health problems; 2) limitations in social activities because of physical or emotional problems; 3) limitations in usual role activities because of physical health problems; 4) bodily pain; 5) general mental health 
(psychological distress and well- being); 6) limitations in usual role activities because of 
emotional problems; 7) vitality (energy and fatigue); and 8) general health perceptions. 
12.2.2. Patient Global Impression of Change ( PGI-C) 
Patient Global Impression of Change ( PGI-C; Appendix 4) is a self -report measure that reflects a 
patient â€™s belief about the efficacy of treatment.  The patient will compare his/her condition from 
the start of the study on a 7-point scale ranging from â€œVery much worseâ€ (1) to â€œVery much 
improvedâ€ (7) at the time of the assessment.  
Protocol Number PTG-300-[ADDRESS_808904] Therapeutics, Inc. 
Protocol Amendment 3 â€“ 14 September  2020 
CONFIDENTIAL AND PROPRIETARY  41 of 67 12.3. Anti -Drug Antibodies (ADA)  
As PTG-[ADDRESS_808905] of ADA on PTG-300â€™s safety and efficacy in that subject will be evaluated. 
Protocol Number PTG-300-[ADDRESS_808906] Therapeutics, Inc. 
Protocol Amendment 3 â€“ 14 September  2020 
CONFIDENTIAL AND PROPRIETARY  42 of 67 13. PHARMACOKI NETIC , PHARMACODYNAMIC AND IRON 
ABSORPTION  ASSESSMENTS  
Trough concentrations of PTG -300 by [CONTACT_610004] . In addition, any additional 
pharmacokinetic parameters t hat can be estimated will be reported.  
13.1. Blood Sample Collection Schedule in Each Study Period  
13.1.1. Sample Collection for All Subjects  
Blood draws to assess concentration  of PTG -300 will be collected during each clinic visit prior 
to a dose of PTG-300 being administered and one day after PTG -300 dose escalation . 
Blood draws to assess iron parameters will be collected during each clinic visit pre -dose 
PTG -300, and one day after each PTG -300 dose escalation . 
See Schedule of Assessments, Table 2 . 
13.1.2. Sample Collection for Iron Absorption Substudy  
Blood samples (5 mL) for measurement of 57Fe, will be collected at the following time points: 
0 (pre -dose 57Fe) and at 4, 8, 12, and [ADDRESS_808907]-dose 57Fe (within 10% nominal time) . 
Blood samples (5 mL) for measurement of iron parameters will be collected pre-dose 57Fe and at 
4, 8, 12, and [ADDRESS_808908]-dose 57Fe (within10% nominal time).  
Blood samples (5 mL) for measurement of concentrations of PTG -300 will be obtained at the 
following time points  during Iron Absorption B : at pre -dose 57Fe, and at 4, 8, 12, and [ADDRESS_808909]-dose 57Fe (within 10% nominal time) . 
See Schedule of Assessments for Iron Absorption substudy, Table [ADDRESS_808910]  
Approximately 11 blood samples for PK and iron parameters (approxima tely 5 mL each) will be 
collected if a subject completes the entire study . In addition, blood samples will be taken for 
assessment of hematology and clinical chemistry. A total of approximately [ADDRESS_808911] Therapeutics, Inc. 
Protocol Amendment 3 â€“ 14 September  2020 
CONFIDENTIAL AND PROPRIETARY  43 of 67 14. ASSESSMENT OF SAFETY  
14.1. Safety Parameters  
Safety will be assessed by [CONTACT_89944]:  
â€¢ ECGs , clinical laboratory tests  including CBC ( Appendix 1),  and physical 
examinations findings (including vital signs). 
â€¢ Adverse events and concomitant medications will be evaluated throughout the course 
of the study. 
â€¢ Adverse events of interest will be assessed and reported separately and include the following: hematological toxicity >  Grade 3 ( CTCAE criteria, Version 5.0). 
Vital signs  will include blood pressure (systolic and diastolic), heart rate, respi[INVESTIGATOR_697] , and 
temperature. 
Electrocardiograms will include ventricular rate, PR, QRS, QT, RR and QTcF. 
The specific timing of safety assessments is  presented in Table [ADDRESS_808912] signs the 
ICF until the completion of the safety follow -up/end of study visit. Treatment- emergent AEs and 
SAEs will be evaluated from study drug dosing until the end of study visit. 
14.2.1. Definition of Adverse Event  
An AE is any event, side effect, or other untoward medical occurrence that occurs in conjunction 
with the u se of a medicinal product in humans, whether or not considered to have a causal 
relationship to this treatment. An AE can, therefore, be any unfavorable and unintended sign (that could include a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to 
the medicinal product. An AE may include an increase in severity of a pre-existing condition 
included in a subjectâ€™s medical history, and symptoms or clinical sequelae of a suspected overdose. â€œLack of efficacyâ€ per se will not be reported as an AE or SAE. However, the signs 
and symptoms and/or clinical sequelae resulting from lack of efficacy will be reported if they 
fulfil the definition of an AE or SAE.  
The Investigator should attempt to establish a diagnosis of the event based on the signs, 
symptoms, and/or other clinical information. In such cases, the diagnosis should be documented 
as the AE (and SAE if serious) and not the individual signs/symptoms. 
[IP_ADDRESS]. Severity of an Adverse Event  
Severity of adverse events will be assessed and reported following CTCAE Version 5.0 criteria  
(National Cancer Institute 2010). Severity of adverse events that do not match CTCAE criteria 
will be assessed as follows:  
â€¢ Mild  (Grade 1) : awareness of sign or symptom but easily tolerated  
Protocol Number PTG-300-[ADDRESS_808913] Therapeutics, Inc. 
Protocol Amendment 3 â€“ 14 September  2020 
CONFIDENTIAL AND PROPRIETARY  44 of 67 â€¢ Moderate (Grade 2) : discomfort enough to cause interference with usual activity  
â€¢ Severe (Grade 3) : incapacitating with inability  to work or do usual activity 
â€¢ Life-threatening  (Grade 4) : could reasonably lead to death without medical 
intervention 
â€¢ Fatal (Grade 5)  
[IP_ADDRESS]. Relationship of an Adverse Event to Study Drug  
The Investigator will assess the relationship between study drug and the occurrence of each AE. 
The investigatorâ€™s assessment of the relationship of each AE to study drug will be recorded in the 
source documents and the CRF. Alternative causes, such as medical history, concomitant 
therapy, other risk factors, and the temporal relationship of the event to the study drug should be considered and investigated, if appropriate. The following definitions are general guidelines to help assign grade of attribution:  
â€¢ Not related:  The event is clearly related to other factors such as the subjectâ€™s clinical 
state, therapeutic interventions or concomitant drugs administered to the subject. This is especially so when an event occurs prior to the commencement of treatment  with 
the study drug. 
â€¢ Unlikely:  The event was most likely produced by [CONTACT_1605]â€™s 
clinical state, therapeutic interventions, or a concomitant drug administered to the subject and does not follow a known response to the study drug. 
â€¢ Possibl y: The event follows a reasonable temporal sequence from the time of study 
drug administration or follows a known response to the study drug but could have 
been produced by [CONTACT_1605]'s clinical state, other therapeutic 
interventions, or concomitant drugs administered to the subject. 
â€¢ Related : The temporal relationship is compelling between the administration of the 
study drug and the AE cannot be explained by [CONTACT_423]â€™s medical condition or other therapi[INVESTIGATOR_014] . 
[IP_ADDRESS]. Action Taken with Study Medications  
Action taken with study medications will be recorded on the AE CRF page, as follows, regardless if a particular category is possible or not in this study: 
â€¢ Dose Increased  
â€¢ Dose Not Changed 
â€¢ Dose Reduced  
â€¢ Dose Interrupted  
â€¢ Dose Withdrawn  
â€¢ Not Applicable 
â€¢ Unknown 
Protocol Number PTG-300-[ADDRESS_808914] Therapeutics, Inc. 
Protocol Amendment 3 â€“ 14 September  2020 
CONFIDENTIAL AND PROPRIETARY  45 of 67 [IP_ADDRESS]. Outcome of an Adverse Event  
Outcome of an AE will be recorded on the AE CRF as follows: 
â€¢ Recovered/Resolved  
â€¢ Recovering/Resolving 
â€¢ Recovered/Resolved with Sequelae  
â€¢ Not Recovered/Not Resolving 
â€¢ Fatal  
â€¢ Unknown 
14.2.2. Definition of Serious Adverse Event  
A serious adverse event (SAE) is any untoward medical occurrence that at any dose:  
â€¢ Results in death  
â€¢ Is life -threatening 
â€¢ Requires inpatient hospi[INVESTIGATOR_1081] 
â€¢ Results in persistent or significant disability/incapacity, or  
â€¢ Is a congenital anomaly/birth defect. 
Important medical events that are not one of the above may be considered to be SAEs by [CONTACT_32845], based upon appropriate medical judgement, they are considered to be 
clinically sig nificant and may jeopardize the subject, or when medical or surgical intervention 
may be required to prevent one of the outcomes listed above. 
An AE is considered â€œlife-threateningâ€ if, in the opi[INVESTIGATOR_609987], 
its occurren ce places the subject at immediate risk of death. It does not include an AE that, had it 
occurred in a more severe form, might have caused death. 
It is important to distinguish between serious and severe AEs. Severity is a measure of intensity, 
whereas ser iousness is defined by [CONTACT_31468]  14.2.2. An AE of severe intensity 
may not be considered serious. 
14.2.3. Pregnancy  
The Investigator must report to the Sponsor any pregnancy occurring in a study subject (or 
subjectâ€™s partner) during the subjectâ€™s participation. The report should be submitted within the same timelines as an SAE, although a pregnancy per se is not considered an SAE unless the birth 
results in a congenital anomaly/birth defect or there is suspi[INVESTIGATOR_609988] a contraceptive medication or method. Spontaneous miscarriages  should also be reported and handled as SAEs. Elective abortions without 
complications should not be handled as AEs. 
A pregnancy should be followed-up until reporting of the pregnancyâ€™s outcome and the birth 
date.  
Protocol Number PTG-300-[ADDRESS_808915] Therapeutics, Inc. 
Protocol Amendment 3 â€“ 14 September  2020 
CONFIDENTIAL AND PROPRIETARY  46 of 67 As information is available, a pregnancy diagnosed during the study will be reported 
immediately to the Investigator and Sponsor (or designee), including pregnancy in female 
partners of male subjects. The pregnancy will be followed to term or outcome and this outcome will be reported to the Sponsor. 
14.2.4. Other Safety Parameters and Related Information 
Additional safety parameters (laboratory tests  including CBC, 12-lead ECGs, physical 
examinations, and vital signs) and concomitant medications are collected as shown in the 
Schedules of Assessments in Table 2. Clinical laboratory assessments are listed in Appendix 1. 
Abnormal findings, other than pharmacodynamic markers, that are deemed clinically significant 
or are associated with signs and/or symptoms must be recorded as AEs (or recorded as an SAE if they meet the criteria of being serious) as described previously. 
The Investigator should exercise his/her medical and scientific judgment in deciding whether an 
abnormal laboratory finding or other abnormal assessment is clinically significant. Usually, the abnormality should be associated with a clinically evident sign or symptom. 
A clinically significant laboratory abnormality in the absence of clinical signs and symptoms 
may jeopardize the subject and may require intervention to prevent immediate consequences. For example, a markedly low serum glucose concentration may not be accompanied by [CONTACT_39597], yet be of a magnitude to require glucose administration to prevent such sequelae. 
14.3. Recording Adverse Events  
Adverse events spontaneously reported by [CONTACT_3184]/or in response to an open question from the study personnel or revealed by [CONTACT_610005]â€™s normal clinical practice and on the AE page of the case report 
form (CRF). SAEs that occur during the study must be documented in the subjectâ€™s medica l 
record, in the AE CRF, and on the SAE form. 
If there is evidence of an AE or SAE through report or observation, the Investigator or designee 
will evaluate further and record the following information: 
â€¢ Time of onset and resolution 
â€¢ Severity  
â€¢ Causality/relation to study treatment 
â€¢ Action taken regarding study drug 
â€¢ Outcome 
14.4. Reporting Adverse Events  
Adverse Events : All AEs, regardless of their relationship to PTG-300, will be reported on the 
AE Case Report Form. In order to ensure timely safety oversight of the trial, AEs should be reported routinely. All reports should include time of onset and resolution, severity ( see 
Section  [IP_ADDRESS]), relationship to PTG-300, action taken regarding PTG-[ADDRESS_808916] Therapeutics, Inc. 
Protocol Amendment 3 â€“ 14 September  2020 
CONFIDENTIAL AND PROPRIETARY  47 of 67 SAEs : In order to meet the requirements for expedited reporting of SAEs to applicable 
regulatory authorities and IRBs, all SAEs, must be reported to the Sponsor within [ADDRESS_808917] is responsible for notifying the relevant regulatory authorities of certain events. It is the Princi pal Investigatorâ€™s responsibility to notify the IRB  or IEC of all SAEs that occur at his 
or her site. Investigators will also be notified of all unexpected, serious, drug-related events (7/15 Day Safety Reports) that occur during the clinical trial. Each s ite is responsible for notifying its 
IRB or IEC of these additional SAEs. 
14.5. Follow- Up of Adverse Events and Serious Adverse Events  
All AEs and SAEs that are deemed possibly related or probably related to PTG -[ADDRESS_808918] to follow -up. The Investigator is responsible to ensure that follow-
up includes any supplemental investigations as may be indicated to elucidate as completely as practical the nature and/or causality of the AE/SAE. This may include additional laboratory tests or investigations, histopathological examinations, or consultation with other health care professionals. 
If a subject dies during participation in the study or during a recognized follow-up period, the 
Sponsor should be provided with a copy of any post-mortem findings, including histopathology. 
Protocol Number PTG-300-[ADDRESS_808919] Therapeutics, Inc. 
Protocol Amendment 3 â€“ 14 September  2020 
CONFIDENTIAL AND PROPRIETARY  48 of 67 15. STATISTICS  
Summary statistics for all efficacy, safety, and PK/PD data, along with the estimation of 
PTG -300's treatment effect, will be provided. A detailed s tatistical analysis plan (SAP) will be 
prepared prior to performing any analysis. In case of differences between the protocol and the 
SAP, the SAP  will take precedence. 
15.1. Study Design and Sample Size Estimation  
This is a multicenter, single- arm, open-label study. 
This trial is exploratory and no rigid criteria for sample size are pre -specified. The choices are 
based on risk/benefit assessment of accumulating results. However, there will be at least 80% 
power for a sample size of [ADDRESS_808920] a 50% reduction in the number of phlebotomies from baseline. The power calculation is based on a hypothesized effect size of 0.5 (mean change = 1, with SD = 2) over [ADDRESS_808921] at  alpha=10% level. Twenty -
eight (28) subjects will be enrolled in the study, assuming an approximate 25% dropout. 
15.2. Demographics/Baseline Comparability  
The demographics and baseline characteristics will be summarized by [CONTACT_10609], with and without 
the iron absorption substudy, respectively,  and overall using descriptive statistics. Demographics 
information includes age, sex, race, and ethnicity. Baseline dis ease characteristics will be 
included if necessary . 
15.3. Data Presentation  
Serum chemistries and measurements related to iron studies will be obtained at the clinical site  
and/or at a central laboratory. The central laboratory value will be used for data presentation and 
study endpoints. The clinical laboratory value may be used for clinical decision making. 
15.4. Definition of Baseline  
For the phlebotomy frequency, the subjectsâ€™ pre-study phlebotomy history will serve as the baseline. For serum ferritin and TSAT, measurements obtained during the screening period will serve as the baseline.  
15.5. Analysis of Efficacy Data  
Efficacy data will be analyzed for all the subjects included in the Intent- to-Treat Analysis Set 
defined below. 
In general, continuous endpoints will be summarized by [CONTACT_262309] (mean, 
standard deviation, median, minimum, and maximum). Categorical endpoints will be summarized by [CONTACT_22977].  
Hypothesis testing will be performed by [CONTACT_941] t-test for each of the change from baseline endpoints listed below to evaluate if the change is signif icantly different from zero. P-value will not be 
adjusted for multiple comparisons since this is an early phase safety and proof of concept study. In addition, the point estimate (i.e., mean and/or median) and the confidence interval associated 
Protocol Number PTG-300-[ADDRESS_808922] Therapeutics, Inc. 
Protocol Amendment 3 â€“ [ADDRESS_808923] 
phlebotomy data.  
Data collected for subjects electing to participate in the iron absorption substudy will be analyzed 
separately in addition to the analyses for all the Intent- to-Treat subjects. Serum iron, 57Fe, TSAT , 
serum ferritin, sTfR, and transferrin pertaining to the iron absorption substudy will be analyzed for the subgroup as defined as Iron Absorption analysis set below.  
15.6. Analysis Populations  
15.6.1. Safety Analysis Set 
The Safety Analysis set will include all subjects  who receive any amount of study drug. 
15.6.2. Intent -to-Treat Analysis Set 
The Intent -to-Treat (ITT) Analysis Set for efficacy analyses  includes all subjects who received 
any study drug and have a baseline and at least one post- baseline efficacy assessment.  
15.6.3. Iron Absorption Analysis Set  
The Iron Absorption (IA ) Analysis Set will include all ITT subjects who complete Iron 
Absorption B. 
15.7. Handling of Missing Data  
Missing data will not be imputed for calculation of mean changes and other quantitative analyses since the aim for those analyses is to estimate mean changes and other quantitative outcomes in subjects who remain on treatment. Missing data are assumed missing at random for subjects remaining on treatment at each respective time point.  
15.8. Analysis of Safety  
The safety analysis will include all subjects who receive any amount of study medication. 
Reported AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA). 
All AEs will be summarized by [CONTACT_610006], for AEs any time during the study. The severity, seriousness, and 
relationship to study medic ation will also be summarized in a similar manner . Each AE (based 
on preferred term) is counted once for a given subject. If the same AE occurred on multiple occasions, the highest severity and least complimentary relationship will be assumed. 
The incidenc e of TEAEs and SAEs will be summarized overall and by [CONTACT_610007], 
respectively . 
Additionally, laboratory test data, physical examinations, vital signs, and ECGs  will be 
summarized overall and by [CONTACT_610007], respectively. 
15.9. Analyses of Pharmacokinetics and Pharmacodynamics  
PK: Concentrations of PTG-[ADDRESS_808924] Therapeutics, Inc. 
Protocol Amendment 3 â€“ 14 September  2020 
CONFIDENTIAL AND PROPRIETARY  50 of 67 PD: 57Fe absorption will be estimated using the AUC in the subgroup of subjects who complete 
both iron absorption treatments. Change from baseline in serum iron parameters (serum iron, 
transferrin, serum ferritin, TSAT) and sTfR  will be estimated . 
In general, descriptive statistics, including the numbers subjects  [n], means, standard deviations 
[SD], medians, minimums , maximums  will be provided for PK parameters as well as for the PD 
parameters.  
15.10.  Exploratory Endpoints  
â€¢ Effects of A DA on safety and efficacy.  
â€¢ The relationship between PTG-[ADDRESS_808925] Therapeutics, Inc. 
Protocol Amendment 3 â€“ [ADDRESS_808926] enrollment, the study 
center will be monitored by a clinical research associate ( CRA ) for compliance, which will 
include ensuring that study procedures are being followed, ensuring that accurate and complete data are recorded on CRFs, and reviewing source documentation and drug accountability records. The study will be conducted according to the principles of GCP. 
16.2. Audits and Inspections  
Authorized representatives of Protagonist, a regulatory authority, an Independent Ethics 
Committee or an Institutional Review Board may visit the site to perform audits or inspections, 
including source data verification. The purpose of a Protagonist audit or inspection is to systematically and independently examine all study- related activities and documents t o 
determine whether these activities were conducted, and data were recorded, analyzed, and accurately reported according to the protocol, Good Clinical Practice guidelines of the International Conference on Harmonization (ICH E6  (R2)), and any other applic able regulatory 
requirements  in the country where the trial takes place. The investigator should contact 
[CONTACT_610008] a regulatory agency about an inspection. 
16.3. Institutional Review Board (IRB) Approval  
Prior to commencement of the study, written approval is required by [CONTACT_610009].  
16.4. Guidelines for Good Clinical Practice  
This study will be conducted in accordance with principles of Good Clinical Practice (GCP) as promulgated by [CONTACT_11580], and applicable regulatory requirements in the country where the trial takes place. Good Clinical Practice is an international ethical and scientific quality standard for 
designing, conducting, recording, and reporting trials that involve the participation of human 
subjects. Compliance with this standard provides public assurance that the rights, safety, and well-being of human subjects are protected under current ethical principles, and that the clinical 
trial data are credible. C urrent GCP standards may be found in ICH Guidance E6 (R2). This 
guidance describes the principles of GCP and the obligations of the institutional review board (IRB), the Investigator and the Sponsor in conducting this study in accordance with those principles.  
16.5. Ethics 
16.5.1. Ethics Review  
The final study protocol, including the final version of the Informed Consent Form, must be approved or given a favorable opi[INVESTIGATOR_57719]. Prior to the 
Protocol Number PTG-300-[ADDRESS_808927] Therapeutics, Inc. 
Protocol Amendment 3 â€“ 14 September  2020 
CONFIDENTIAL AND PROPRIETARY  52 of 67 commencement of the study, written approval will be required by [CONTACT_56335]/ IEC 
responsible for the investigational site. 
In addition, the IRB or IEC must approve all advertising used to recruit subject s for the study. 
The investigator must submit written approval to Protagonist before he or she can enroll any 
patient/subject into the study. 
The Principal Investigator [INVESTIGATOR_14495]. The protocol must be re-approved by [CONTACT_55398], as local regulations require. 
The Principal Investigator [INVESTIGATOR_609989]. Protagonist will provide this information to the Principal Investigator.  
Progress reports and notifications of serious adverse drug reactions will be provided to the IRB or IEC according to local regulations and guidelines. 
16.5.2. Ethical Conduct of the Study  
The study will be performed in accordance with ethical principles that have their origin in the 
Declaration of Helsinki and are consistent with ICH/Good Clinical Practice  and applicable 
regulatory requirements. 
16.5.3. Written Informed Consent  
A properly executed, written  Informed Consent Form, in compliance with the Declaration of 
Helsinki, ICH GCP, and U nited States ( US) Code of Federal Regulations for Protection of 
Human Subjects (21 CFR 50.25[a,b], CFR 50.27, and CFR Part 46, Subpart A), will be 
explained  to and signed by [CONTACT_596832]. The Investigator will provide a 
copy of the signed Informed Consent Form to each subject and will maintain a copy in the 
subjectâ€™s record file.  
16.6. Termination of Study  
The Sponsor has the ri ght to terminate this study and remove all study material from the site at 
any time for medical or administrative reasons. In this event, the Sponsor will endeavor to give adequate notice to allow safe withdrawal of subjects from the study. 
16.7. Case Report For ms 
Site personnel should collect and record data for the study as source documents and transfer the data into the CRF. 
The Investigator must ensure that complete data for the clinical study are collected and 
accurately documented in the appropriate section s of the CRF and adequately supported by [CONTACT_89952]. In addition, it is the Investigatorâ€™s responsibility to provide signatures where requested indicating concurrence with data in the CRF. 
Protocol Number PTG-300-[ADDRESS_808928] Therapeutics, Inc. 
Protocol Amendment 3 â€“ [ADDRESS_808929]. 
16.9. Retention of Records  
International Conference on Harmonization, GCP, and US Food and Drug Administration (F DA) 
guidelines require that essential documents be retained until at le ast [ADDRESS_808930]. 
However, the essential documents should be retained for a longer period if required by [CONTACT_222343]. Records should never be destroyed without written approval from the Sponsor. 
If an Investigat or leaves the institution, he/she must transfer responsibilities for record retention 
to another individual willing to accept them. The Investigator must notify the Sponsor in writing 
of the transfer of study documents before the transfer of the study. 
Protocol Number PTG-300-[ADDRESS_808931] Therapeutics, Inc. 
Protocol Amendment 3 â€“ [ADDRESS_808932]â€™s Publication Policy. Subject confidentiality will be maintained by [CONTACT_610010]. Publication of results will be subjected to fair peer- review.  
Authorship on any publication of the results from this study will be based on contributions to study design, enrolment, data analysis, and interpretation of results according to International 
Committee of Medical Journal Editors guidelines (http://www.icmje.org ). All conflicts arising 
through disputes about authorship will be reviewed by [CONTACT_610011]. 
Acknowledgment will be given to collaborating institutions and hospi[INVESTIGATOR_609990]. 
In the case of no publication, information will only be released to the public and media in 
accordance with Protagonistâ€™s Policy. 
Protocol Number PTG-300-[ADDRESS_808933] Therapeutics, Inc. 
Protocol Amendment 3 â€“ 14 September  2020 
CONFIDENTIAL AND PROPRIETARY  55 of 67 18. REFERENCES 
Bodamer OA, Halliday D. Uses of stable isotopes in clinical diagnosis and research in the 
paediatric population. Arch Dis Child. 2001 May;84(5):444-8. 
Brissot P, Bardou-Jacquet E, Jouanolle AM, Loreal O. Iron disorders of genetic origin: a 
changing world. Trends Mol Med. 2011;17(12): 707-713. 
Camaschella C . Iron and hepcidin: a story of recycling and balance. Hematology Am Soc 
Hematol Ed u Program. 2013; 2013:1-8. 
Crownover BK, Covey CJ. Hereditary hemochromatosis. Am Fam Physician. 2013;87(3):183-
90. 
Katsarou MS, Papasavva M, Latsi R, Drakoulis N. Hemochromatosis: Hereditary 
hemochromatosis and HFE gene. Vitam Horm. 2019;110:201-222. 
Liu J, Sun B, Yin H, Liu S. Hepcidin: A Promising Therapeutic Target for Iron Disorders: A 
Systematic Review. Medicine (Baltimore). 2016 Apr;95(14):e3150. 
National  Cancer Institute, National Institutes of Health (NIH) Publication No. 09-540. Common 
Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Bethesda, MD: National Cancer Institute, Published November 27, 2017. Available at 
https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_R
eference_5x7.pdf . Accessed October 31, 2018. 
Ramos E, Ruchala P, Goodnough JB, Kautz L, Preza GC, Nemeth E, Ganz T. Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis. Blood. 2012 Nov 1;120(18):3829-36. 
Ruchala P, Nemeth E. The pathophysiology and pharmacology of hepcidin. Trends Pharmacol 
Sci. 2014 Mar;35(3):155-61. 
Ware JE Jr, Sherbourne CD. The MOS 36- item short- form hea lth survey (SF-36).I. Conceptual 
framework and item selection. Med Care. 1992 Jun;30(6):473-83. 
 
Protocol Number PTG-300-[ADDRESS_808934] Therapeutics, Inc. 
Protocol Amendment 3 â€“ [ADDRESS_808935] Therapeutics, Inc. 
Protocol Amendment 3 â€“ [ADDRESS_808936] S 
 
HEMATOLOGY/CBC  
hemoglobin hematocrit  
red blood cell count 
white blood cell count 
% neutrophils % lymphocytes % monocytes % basophils 
% eosinophils 
absolute neutrophils absolute lymphocytes absolute monocytes absolute basophils 
absolute eosinophils 
platelet count  
CHEMISTRY  
sodium potassium chloride 
carbon dioxide 
blood urea nitrogen (BUN) creatinine  
glucose calcium  
phosphorous albumin  
total protein  
uric acid  
total bilirubin  
direct bilirubin  indirect bilirubin  
alkaline phosphatase 
alanine aminotransferase 
(ALT, SGPT)  
aspartate aminotransferase (AST, SGOT)  
lactate dehydrogenase  
(LDH)
URINALYSIS  
pH 
specific gravity  
blood glucose ketones 
microscopic exam (RBC 
and WBC, only when indicated)  
leukocyte esterase  protein
Protocol Number PTG-300-[ADDRESS_808937] Therapeutics, Inc.  
Protocol Amendment 3 â€“ [ADDRESS_808938] (to be completed on site) for female subjects of childbearing potential at 
Screening  and at Safety Follow -Up (Week 29)  
Urine pregnancy test (to be completed on site) for female subjects of childbearing potential. 
Protocol Number PTG-300-[ADDRESS_808939] Therapeutics, Inc.  
Protocol Amendment 3 â€“ 14 September  2020 
CONFIDENTIAL AND PROPRIETARY  59 of 67 APPENDIX  2. ADDITIONAL LABORATORY TESTS 
 
The following samples to be collected as per Schedule of Assessments ( Table 2 ). 
 IRON PARAMETERS  (PHARMACODYNAMIC PARAMETERS)  
serum iron  
serum ferritin  
transferrin  
TSAT  
 ADDITIONAL ASSESSMENTS  
sTfR 
hepcidin ADA  
Protocol Number PTG-300-[ADDRESS_808940] Therapeutics, Inc.  
Protocol Amendment 3 â€“ 14 September  2020 
CONFIDENTIAL AND PROPRIETARY  60 of 67 APPENDIX  3. MEDICAL OUTCOME STUDY  QUESTIONNAIRE 
SHORT FORM HEALTH SURVEY  (SF-36) 
 
  
Protocol Number PTG-300-[ADDRESS_808941] Therapeutics, Inc.  
Protocol Amendment 3 â€“ [ADDRESS_808942] Therapeutics, Inc.  
Protocol Amendment 3 â€“ [ADDRESS_808943] Therapeutics, Inc.  
Protocol Amendment 3 â€“ [ADDRESS_808944] Therapeutics, Inc.  
Protocol Amendment 3 â€“ [ADDRESS_808945] Therapeutics, Inc.  
Protocol Amendment 3 â€“ [ADDRESS_808946] Therapeutics, Inc.  
Protocol Amendment 3 â€“ [ADDRESS_808947] Therapeutics, Inc.  
Protocol Amendment 3 â€“ 14 September  2020 
CONFIDENTIAL AND PROPRIETARY  67 of 67 APPENDIX  4. PATIENT GLOBAL IMPRESSION OF CHANGE (PGI -C) 
 
The subject will independently rate the following question of Patient Global Impression of 
Change (PGI-C) based on his/her overall impression at  Week 9 and Week  25. 
 
Patient Global Impression of Change: 
Compared to your condition prior to your starting on this study, how much has your condition 
changed with your current treatment? 
 
ï± 1 ï± 2 ï± 3 ï± 4 ï± 5 ï± 6 ï± 7 
Very 
Much 
Worse  Much 
Worse  Minimally 
Worse  No 
Change Minimally 
Improved Much 
Improved Very 
Much 
Improved 
 